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Abstract 1 
 2 
The extent and dynamics of animal cell biomass accumulation during mitosis are unknown, 3 
primarily because growth has not been quantified with sufficient precision and temporal resolution. 4 
Using the suspended microchannel resonator and protein synthesis assays, we quantify mass 5 
accumulation and translation rates between mitotic stages on a single-cell level. For various animal 6 
cell types, growth rates in prophase are commensurate with or higher than interphase growth rates. 7 
Growth is only stopped as cells approach metaphase-to-anaphase transition and growth resumes in 8 
late cytokinesis. Mitotic arrests stop growth independently of arresting mechanism. For mouse 9 
lymphoblast cells, growth in prophase is promoted by CDK1 through increased phosphorylation of 10 
4E-BP1 and cap-dependent protein synthesis. Inhibition of CDK1-driven mitotic translation reduces 11 
daughter cell growth. Overall, our measurements counter the traditional dogma that growth during 12 
mitosis is negligible and provide insight into antimitotic cancer chemotherapies. 13 
 14 
 15 
Impact statement 16 
High resolution single-cell mass accumulation and protein synthesis rate measurements are used to 17 
quantify the extent, dynamics and consequences of animal cell growth in mitosis and cytokinesis. 18 
  19 
3 
 
Introduction 20 
 21 
Animal cell growth, i.e. biomass accumulation (Lloyd, 2013), is classically viewed to take place 22 
during interphase. During mitosis and cytokinesis, when cells are assumed to prioritize their energy 23 
usage for executing cell division, growth is presumed to be minimal (reviewed in (Kronja and Orr-24 
Weaver, 2011; Pyronnet and Sonenberg, 2001; Salazar-Roa and Malumbres, 2017; Sivan and 25 
Elroy-Stein, 2008; White-Gilbertson et al., 2009)). More specifically, mRNA synthesis is inhibited 26 
due to chromatin condensation and dissociation of transcription factors (Liang et al., 2015; Novais-27 
Cruz et al., 2018; Parsons and Spencer, 1997; Prescott and Bender, 1962), and ribosomal RNA 28 
synthesis is blocked as the nucleolus disappears in prometaphase (Hernandez-Verdun, 2011). 29 
Protein synthesis has also been reported to be suppressed in cell populations enriched for mitosis 30 
(Bonneau and Sonenberg, 1987; Celis et al., 1990; Fan and Penman, 1970; Prescott and Bender, 31 
1962; Pyronnet et al., 2001; Sivan et al., 2011; Sivan et al., 2007). Consistently, polysome and 32 
ribosome profiling studies have suggested that the translational efficiency of most mRNAs is 33 
reduced in mitosis (Park et al., 2016; Qin and Sarnow, 2004; Stumpf et al., 2013; Tanenbaum et al., 34 
2015). Studies on individual components of the translational machinery, such as eukaryotic 35 
Translation Initiation Factor 4E (eIF4E), eIF4E Binding Protein 1 (4E-BP1), eukaryotic Translation 36 
Elongation Factor 2 (eEF2) and S6 Ribosomal Protein (S6RP) have also suggested reduced protein 37 
synthesis, especially cap-dependent translation initiation, in mitosis (Celis et al., 1990; Dobrikov et 38 
al., 2014; Pyronnet et al., 2001; Shah et al., 2003; Wilker et al., 2007). Furthermore, ribosomes 39 
disassociate from endoplasmic reticulum around metaphase, suggesting that translation may be 40 
limited in the middle of mitosis (Puhka et al., 2007).  41 
However, this classical view that growth is inhibited during mitosis has recently been 42 
challenged. Parts of DNA remain accessible for transcription machinery and de novo transcription 43 
of genes involved in cell growth persists in mitosis (Chan et al., 2012; Chen et al., 2005; Liu et al., 44 
2017; Palozola et al., 2017). Recent reports also suggest that protein synthesis may persist during 45 
mitosis (Coldwell et al., 2013; Shuda et al., 2015; Stonyte et al., 2018). Importantly, Cyclin 46 
Dependent Kinase 1 (CDK1), the key regulator of mitotic entry and progression (Diril et al., 2012; 47 
Gavet and Pines, 2010), phosphorylates and activates components of the protein synthesis 48 
machinery, including 4E-BP1 (Heesom et al., 2001; Jansova et al., 2017; Shuda et al., 2015), eEF2 49 
kinase (Smith and Proud, 2008) and p70 S6 kinase (Papst et al., 1998), suggesting an activation of 50 
cap-dependent translation. In addition, cap-independent translation of many mRNAs remains active 51 
in mitosis (Cornelis et al., 2000; Marash et al., 2008; Pyronnet et al., 2000; Qin and Sarnow, 2004). 52 
It is therefore becoming evident that particular proteins, especially those required for completion of 53 
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cell division and those critical for cell growth, are synthesized during mitosis (Aviner et al., 2013; 54 
Aviner et al., 2017; Cornelis et al., 2000; Marash et al., 2008; Park et al., 2016; Pyronnet et al., 55 
2000; Stumpf et al., 2013; Tanenbaum et al., 2015). However, the extent and dynamics of protein 56 
synthesis in mitosis remain unclear. 57 
Importantly, protein and RNA synthesis rates are only proxies of overall growth 58 
(biomass increase), which is determined by the balance between synthesis (anabolic) and 59 
degradation (catabolic) rates (Lloyd, 2013; Miettinen and Bjorklund, 2015; Miettinen et al., 2017). 60 
Overall growth behavior during mitosis has not been studied, primarily due to the lack of precise 61 
cell size measurement methods that are sensitive enough to quantify growth during the short mitotic 62 
stages. Here we utilize suspended microchannel resonator (SMR), a high precision microfluidic 63 
mass sensor, and protein synthesis assays in conjunction with cell cycle measurements to study the 64 
extent, dynamics, mechanisms and consequences of mitotic growth on a single-cell level. 65 
 66 
 67 
Results 68 
 69 
Animal cells grow during mitosis and cytokinesis 70 
SMR is a microfluidic cantilever that is capable of measuring buoyant mass (a proxy 71 
of dry mass, referred to as mass from here on) of single cells with a precision of <0.1 pg (Figure 1a; 72 
Figure 1–figure supplement 1a-d) (Burg et al., 2007; Son et al., 2015a; Son et al., 2012). This 73 
resolution corresponds to <8 nm (<0.07%) change in a spherical lymphocyte cell diameter. We 74 
repeatedly measured mass of the same cell every ~1 min, resulting in a temporal resolution of 75 
approximately 2 min according to the Nyquist rate. We quantified growth, more specifically mass 76 
accumulation, throughout multiple cell cycles in L1210 mouse lymphocytes without perturbing 77 
normal growth rates (Figure 1b) (Son et al., 2015a; Son et al., 2012). We assigned approximate 78 
mitotic entry (i.e. G2/M transition), metaphase-to-anaphase transition (i.e. M/A transition) and 79 
cytokinetic abscission of the daughter cells for each cell using biophysical properties and FUCCI 80 
cell cycle reporter (Figure 1–figure supplement 2; Materials and methods) (Kang et al., 2019). This 81 
allowed quantification of mass accumulation during early mitosis (between G2/M transition and 82 
M/A transition) and cytokinesis (between M/A transition and daughter cell abscission) on a single-83 
cell level (Figure 1c). In cytokinesis the elongated cells register smaller than round cells in our mass 84 
measurements, because of a change in mass distribution (Kang et al., 2019). Correcting for this cell 85 
elongation induced bias (correction is applied to all data shown, unless otherwise stated) (see 86 
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Materials and methods), had little influence of the mass measurements during cytokinesis (Figure 87 
1–figure supplement 1e). 88 
In total, we analyzed 180 individual L1210 cells undergoing mitosis and observed that 89 
on average 12% of the total mass accumulated during the whole cell cycle was acquired during M-90 
phase (i.e. during mitosis & cytokinesis) (Figure 1d; Figure 1–source data 1). 7% of total cell 91 
growth took place during early mitosis, while 5% took place during cytokinesis. During anaphase, 92 
duration of which was estimated based on cell elongation (Materials and methods), mass 93 
accumulation was negligible. Considering that in most cell lines M-phase lasts approximately 10% 94 
of the whole cell cycle, the 12% mass accumulation observed during M-phase makes M-phase 95 
growth comparable to interphase growth. 96 
The extent of total cell growth during mitosis and cytokinesis was surprising. To 97 
determine how generalizable this finding is, we repeated our measurements in other animal cell 98 
types. Mouse FL5.12 and BaF3 pro-B lymphocytes, and chicken DT40 lymphoblasts grew 9-13% 99 
of their total mass in M-phase (Figure 1d). Suspension HeLa (S-HeLa) cells also grew 14% of their 100 
total mass during M-phase, validating that substantial growth in M-phase is not specific to 101 
lymphocytes. We also examined CD3+ and CD8+ activated primary human T cells. Both T-cell 102 
subpopulations added approximately 7% of their total mass during M-phase. Thus, growth in 103 
mitosis and cytokinesis is an important contributor to the total cellular growth across a variety of 104 
cell types grown in suspension. 105 
 106 
Cell mass accumulation persists through prophase, stops as cells approach metaphase-to-107 
anaphase transition and recovers during late cytokinesis 108 
To study the dynamics of cell growth during M-phase, we quantified the absolute 109 
mass accumulation rates (MAR) before and during M-phase (Figure 2–figure supplement 1; 110 
Materials and methods). To account for cell size dependent growth rates (Miettinen and Bjorklund, 111 
2016; Miettinen et al., 2017; Son et al., 2012), we normalized MAR to the mass of the cell 112 
(MAR/mass). Surprisingly, after mitotic entry (during approximate prophase) L1210 cells exhibited 113 
on average 15.8±3% (mean±SEM, n=180) increase in MAR when compared to late G2 phase 114 
(Figure 2a,b). As cells approached the metaphase-to-anaphase transition, MAR rapidly decreased 115 
and eventually reached zero at the end of metaphase. MAR remained near zero for the approximate 116 
duration of anaphase, after which MAR started to recover during late cytokinesis (Figure 2a,c,d). 117 
The recovery of MAR continued through the abscission of daughter cells (Figure 2d). These cell 118 
growth dynamics also persisted under different nutrient conditions and were reproducible with 119 
different SMR devices over multiple years of study (Figure 2–figure supplement 2a,c). 120 
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We next examined MAR in other cell types. Although increased MAR during early 121 
mitosis was only observed in some cell types, MAR remained high after mitotic entry (during 122 
approximate prophase) for all the cell types studied (Figure 2e; Figure 2–figure supplement 2b). All 123 
cell types displayed rapid reduction of MAR during metaphase (possibly starting in late 124 
prometaphase), near zero MAR during anaphase and a recovery of MAR during late cytokinesis. 125 
The temporary stop of cell growth in anaphase was consistently short (<15min) and coincided with 126 
the physical separation of the daughter cells (Figure 2c-e). Notably, some cells displayed a negative 127 
MAR, indicating a small loss of cell mass during late metaphase and/or early anaphase (Figure 2e; 128 
Figure 2–figure supplement 2b). Together, these results indicate that the mitotic growth behavior is 129 
conserved across various animal cell types in suspension, suggesting a role for these specific growth 130 
dynamics during mitosis. 131 
 132 
Mitotic protein synthesis rates are consistent with mitotic MAR dynamics 133 
Proteins constitute approximately 70% of cellular dry mass (Palm and Thompson, 134 
2017), making it likely that the measured MAR dynamics reflect protein synthesis rates. Using 135 
L1210 cells as a model, we quantified the dynamics of mitotic protein synthesis using O-propargyl-136 
puromycin (OPP) based single-cell protein synthesis assays (Liu et al., 2012) together with a 137 
mitotic marker (phospho-Histone H3 (Ser10)) (Figure 3a; Figure 3–figure supplement 1a,b; 138 
Materials and methods). For unsynchronized cells, the average mitotic protein synthesis rates were 139 
85±6% (mean±SD, n=6) of the rate for G2 cells. We then synchronized cells using double 140 
thymidine block followed by CDK1 inhibitor (RO-3306) mediated G2 arrest and a release, which 141 
was followed by 10 min OPP labelling at various timepoints. We normalized mitotic protein 142 
synthesis rates to G2 protein synthesis rates to avoid cell synchronization induced biases (Figure 143 
3a). Immediately after the release from G2 arrest, when mitotic cells were in prophase, protein 144 
synthesis rates were higher in mitotic cells than in G2 cells (Figure 3b). Approximately 30 min 145 
later, when most mitotic cells proceeded to cytokinesis, the protein synthesis rates were reduced to 146 
below the normal G2 levels. 147 
 To validate that the observed protein synthesis dynamics are not an artefact of cell 148 
synchronization, we utilized a previously developed approach where Cyclin A, which is degraded 149 
during prometaphase (den Elzen and Pines, 2001), is used to separate early (prophase) and late 150 
(metaphase to telophase) mitotic cells (Ly et al., 2017) (Figure 3c). In the absence of cell cycle 151 
synchronization, OPP based protein synthesis assay indicated that early mitotic cells have higher 152 
protein synthesis rates than G2 cells, whereas in late mitotic cells, protein synthesis is reduced 153 
(Figure 3d). We also separated G2, early mitosis and late mitosis based on cyclin B1, which is 154 
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degraded at metaphase-to-anaphase checkpoint (Figure 3–figure supplement 1a). This approach also 155 
revealed that protein synthesis rates remain high in early mitosis but not in late mitosis (Figure 3–156 
figure supplement 1c). Although protein synthesis assays do not have temporal resolution required 157 
for separation of all mitotic stages, the protein synthesis dynamics we observe correspond to those 158 
observed with MAR measurements. In conclusion, L1210 cells display increased growth in early 159 
mitosis and radically reduced growth in metaphase and anaphase. 160 
 161 
Mitotic arrests, including antimitotic chemotherapies, inhibit cell growth  162 
Our results show that growth is inhibited from metaphase (or late prometaphase) to 163 
the end of anaphase (Figure 2a). As many studies examine mitotic growth by arresting cells to 164 
mitosis, and this has been suggested to reduce cell growth (Coldwell et al., 2013; Sivan et al., 2011; 165 
Stonyte et al., 2018), we measured the effect of chemically induced mitotic arrest on cell growth. 166 
First, we monitored the MAR of L1210 cells treated with kinesin inhibitor S-trityl-l-cysteine 167 
(STLC), which arrests cells in prometaphase state. These cells displayed a growth burst in early 168 
mitosis, similarly to untreated cells, after which MAR approached zero over the course of 2-3 hours 169 
(Figure 4a). We also repeated our mitotic protein synthesis assay (Figure 3a) in the presence of 170 
STLC. Similarly to MAR, protein synthesis rates increased after mitotic entry, but then gradually 171 
decreased as cells were arrested in mitosis (Figure 4b). 172 
To separate drug specific effects on growth from those that reflect mitotic arrest, we 173 
tested three additional chemical approaches for arresting cells in mitosis. These were microtubule 174 
inhibitor nocodazole, proteasome inhibitor MG-132 and Anaphase-Promoting Complex inhibitor 175 
proTAME (Zeng et al., 2010). All these chemicals resulted in similar reduction in the overall 176 
mitotic protein synthesis (Figure 4c). None of these chemicals caused protein synthesis to be 177 
significantly reduced in G2, except for MG-132. In addition, nocodazole treatment resulted in 178 
identical MAR behavior as STLC (Figure 4a).  179 
Mitotic arrest is the mechanism of action for many chemotherapy drugs. We examined 180 
how clinically relevant concentrations of the chemotherapy drugs Vinblastine and Vincristine 181 
(Florian and Mitchison, 2016) affect cell MAR. Neither of the drugs affected cell growth in G2, but 182 
as cells were arrested in mitosis, their growth rate reduced to zero (Figure 4d). Thus, mitotic arrests, 183 
including antimitotic chemotherapies, stop cell growth independently of the arresting mechanism. 184 
 185 
Cells in metaphase and anaphase display mitotic stage specific inhibition of mass 186 
accumulation 187 
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Next, we studied if metaphase and anaphase, where MAR was near zero, have a 188 
growth reducing mechanism(s) that is not active earlier in mitosis. We first considered the role of 189 
mitotic deswelling. During mitosis cells round up and increase their volume by approximately 10-190 
20%, before shrinking (deswelling) back to their original volume during anaphase (Son et al., 191 
2015a; Zlotek-Zlotkiewicz et al., 2015). While mitotic rounding has minimal influence on the cell 192 
types used in this study, as the suspension cells display a spherical morphology throughout the cell 193 
cycle, inhibition of mitotic cell swelling removed the MAR increase seen in early mitosis but did 194 
not affect MAR in metaphase and anaphase (Figure 5–figure supplement 1a-c). Furthermore, 195 
inhibition of mitotic swelling did not influence early mitotic protein synthesis rates (Figure 5–figure 196 
supplement 1d). Thus, while mitotic swelling influences the MAR observed in early mitosis, 197 
possibly by increasing cell mass due to the uptake of ions, this does not explain why cells suddenly 198 
stop growing around metaphase-to-anaphase transition.  199 
Next, we examined if cytokinetic cell elongation is required for the near zero (or even 200 
negative) MAR around metaphase-to-anaphase transition. We treated L1210 cells with Tozasertib, 201 
an Aurora kinase inhibitor, which blocks cytokinesis but not mitosis as evident from the loss of 202 
Geminin (Figure 5a). Tozasertib treated cells displayed low MAR around metaphase-to-anaphase 203 
transition, although MAR remained higher than in control cells (Figure 5b; Figure 5-figure 204 
supplement 2a). We then treated cells with blebbistatin, a myosin motor inhibitor which also blocks 205 
cytokinesis (Atilla-Gokcumen et al., 2010). Blebbistatin treatment resulted in MAR dynamics 206 
comparable to control cells (Figure 5-figure supplement 2b). In addition, both Tozasertib and 207 
blebbistatin prolonged the duration of early mitosis. Together, these data indicate that the physical 208 
separation of daughter cells does not explain the observed MAR dynamics.  209 
The radical reduction in MAR observed as cells approach metaphase-to-anaphase 210 
transition could be explained by two separate mechanisms: First, growth may be reduced as a 211 
function of time after mitotic entry, or possibly after an initial delay in growth reduction. This 212 
hypothesis is supported by the gradual decrease in growth rates following mitotic arrests (Figure 4), 213 
possibly because of the inhibition of transcription as DNA condenses. Second, there may be a 214 
separate growth inhibiting mechanism(s) specific to metaphase and anaphase. To separate these two 215 
options, we compared the MAR as a function of time from mitotic entry in control cells and cells 216 
arrested in prometaphase state using STLC (Figure 5c). 20 min after mitotic entry, when cells are in 217 
late prometaphase, both samples displayed similar growth rates (Figure 5d). However, 28 min and 218 
32 min after mitotic entry, when control cells had proceeded to metaphase and anaphase, 219 
respectively, but STLC treated cells remained arrested in prometaphase, the control cells displayed 220 
lower MAR. Similar results were obtained when prometaphase arrest was achieved using 221 
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Nocodazole (Figure 5–figure supplement 2c). In conclusion, the mitotic morphological changes 222 
(Figure 5a,b; Figure 5-figure supplement 1; Figure 5-figure supplement 2a,b) and the time that cells 223 
have spent in mitosis cannot fully explain the observed MAR in metaphase and anaphase. Thus, 224 
additional MAR reducing mechanism(s) must exist around metaphase-to-anaphase transition. 225 
 226 
Mitotic growth does not require mTOR activity 227 
We then investigated what signaling promotes growth and protein synthesis in mitosis 228 
(Figure 6a). We measured the levels of phosphorylated 4E-BP1 (Thr37/46) and S6RP (Ser235/236) 229 
at the single-cell level in mitotic and G2 L1210 cells. Mechanistic Target Of Rapamycin (mTOR) 230 
regulates both of these proteins, which in turn control translation (Fingar et al., 2004). Importantly, 231 
4E-BP1 is a negative regulator of translation and is inactivated by phosphorylation on several sites, 232 
including Thr37/46 (reviewed by (Qin et al., 2016)). Phosphorylated 4E-BP1 levels were 233 
approximately 3-fold higher in mitosis than in G2 (Figure 6b; Figure 6-figure supplement 1), 234 
whereas phosphorylated S6RP displayed only a minor increase in mitosis (Figure 6–figure 235 
supplement 2a). The mitotic phosphorylation of 4E-BP1 was validated with an independent 236 
antibody using microscopy and the mitotic increase was not observed when using antibody isotype 237 
controls or pretreating the sample using Lambda protein phosphatase (Figure 6–figure supplement 238 
1). The mitotic phosphorylation of 4E-BP1 is also consistent with previous reports (Shuda et al., 239 
2015) and the observation that the translational targets of mTOR are actively translated during 240 
mitosis (Park et al., 2016). 241 
To examine the role of mTOR, we treated cells for 2 h with 250 nM mTOR inhibitor 242 
TORIN-1. In G2 cells the levels of phosphorylated 4E-BP1 (Thr37/46) and S6RP (Ser235/236) 243 
were near zero (Figure 6b; Figure 6–figure supplement 2b). In mitosis, phosphorylation of S6RP 244 
was reduced by TORIN-1 (Figure 6–figure supplement 2b), indicating that mTOR remains active in 245 
mitosis. However, TORIN-1 did not change the levels of phosphorylated 4E-BP1 in mitosis (Figure 246 
6b), suggesting that a mTOR independent mechanism activates 4E-BP1 in mitosis. Next, we 247 
measured mitotic protein synthesis rates in the presence of TORIN-1. Although G2 protein 248 
synthesis rates were reduced, mitotic protein synthesis rates were not affected by TORIN-1 (Figure 249 
6–figure supplement 2c). Thus, mTOR is not a major contributor to mitotic growth. 250 
 251 
CDK1 drives phosphorylation of 4E-BP1, protein synthesis and mass accumulation in mitosis 252 
We examined how the levels of phosphorylated 4E-BP1 (Thr37/46) and S6RP 253 
(Ser235/236) change when CDK1 is inhibited with 1 µM RO-3306 (Vassilev et al., 2006). At this 254 
RO-3306 concentration, L1210 cells can still progress through mitosis, as CDK1 is only partially 255 
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inhibited (Son et al., 2015a). Only in mitosis did RO-3306 reduce phosphorylated 4E-BP1 but not 256 
phosphorylated S6RP (Figure 6b; Figure 6–figure supplement 2b). Although the role of CDK1 in 257 
controlling 4E-BP1 phosphorylation has been reported before (Heesom et al., 2001; Shuda et al., 258 
2015), the consequences of this on protein synthesis and cell growth remain unknown. We observed 259 
that 1 µM RO-3306 treatment also reduced mitotic protein synthesis rates without affecting G2 260 
protein synthesis rates (Figure 6c). In addition, RO-3306 treatment prolonged early mitosis and 261 
resulted in a clear reduction of MAR in mitosis but not in G2 (Figure 6d).  262 
To further validate the role of CDK1 in promoting mitotic growth, we utilized 263 
chemical genetics in the DT40 CDK1as cell line. In these cells the wild-type CDK1 has been 264 
replaced with Xenopus laevis CDK1 that has a F80G mutation (Gibcus et al., 2018), which 265 
sensitizes CDK1 to inhibition by the ATP analog 1NM-PP1 (Hochegger et al., 2007). We observed 266 
that protein synthesis was reduced by 1NM-PP1 in a dose dependent manner in mitosis but not in 267 
G2 (Figure 6e). Consistently, 1NM-PP1 also reduced MAR in mitosis (Figure 6f).  268 
We also investigated the role of other mitotic kinases in promoting protein synthesis 269 
and cell growth. Inhibitors for CDK2, Aurora kinases and DYRK kinases did not affect mitotic 270 
protein synthesis (Figure 6–figure supplement 3a). OTSSP167, a drug designated as a MELK 271 
inhibitor (Chung et al., 2012), reduced phosphorylation of 4E-BP1, protein synthesis and mass 272 
accumulation rates in mitosis (Figure 6b-d). Consistently, MELK has been suggested to promote 273 
translation in mitosis (Wang et al., 2016). However, alternative MELK inhibitors (Klaeger et al., 274 
2017) did not display mitosis specific inhibition of protein synthesis (Figure 6–figure supplement 275 
3b,c), suggesting that the mitotic growth effects observed in OTSSP167 treated cells were not 276 
mediated by MELK but by OTSSP167 off-targets. 277 
We then moved to validate that 4E-BP1 mediates the CDK1 driven protein synthesis. 278 
We generated two L1210 cell lines expressing 4E-BP1 targeting shRNAs, which reduced 4E-BP1 279 
levels by approximately 85% (shRNA #1) and by 50% (shRNA #2) (Figure 6–figure supplement 280 
4a,b). The 4E-BP1 knockdowns had little effect on proliferation rate (Figure 6–figure supplement 281 
4c) or G2 cell protein synthesis (Figure 6g), possibly reflecting that 4E-BP1 is kept mostly inactive 282 
under our experimental conditions. However, when we reduced mitotic protein synthesis by 283 
inhibiting CDK1 with RO-3306, the knockdowns of 4E-BP1 partially rescued the mitotic protein 284 
synthesis inhibition (Figure 6g). These data indicate that CDK1 promotes mitotic growth at least 285 
partly through 4E-BP1. 286 
4E-BP1-driven cap-dependent protein synthesis is classically considered to be 287 
inhibited in mitosis (Bonneau and Sonenberg, 1987; Pyronnet et al., 2001), although recently this 288 
view has been challenged (Coldwell et al., 2013; Shuda et al., 2015). We therefore tested if i) cap-289 
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dependent translation remains active in L1210 cell mitosis, and if ii) cap-dependent translation is 290 
required for CDK1 mediated mitotic growth. To test these, we first inhibited cap-dependent 291 
translation using 4EGI-1, an inhibitor of eIF4F complex assembly (Cencic et al., 2011). Both G2 292 
and mitotic protein synthesis rates were reduced by a similar amount, approximately 50%, 293 
following 4EGI-1 treatment (Figure 6h). However, treatment with both 4EGI-1 and RO-3306 did 294 
not significantly change mitotic protein synthesis rates when compared to treatment with 4EGI-1 295 
alone, suggesting that cap-dependent protein synthesis is involved in CDK1-driven mitotic 296 
translation. In conclusion, our results are consistent with a previous report (Shuda et al., 2015) that 297 
CDK1 substitutes for mTOR in mitosis to promote phosphorylation of 4E-BP1, to maintain cap-298 
dependent translation and to promote mass accumulation. 299 
 300 
CDK1-driven mitotic protein synthesis supports daughter cell growth 301 
Mitotic transcription and translation have been suggested to be geared towards 302 
ribosomal proteins and other components that promote growth (Aviner et al., 2017; Palozola et al., 303 
2017). Therefore, inhibiting mitotic protein synthesis could also impact growth in cytokinesis and in 304 
daughter cells. We compared the MAR of RO-3306 or OTSSP167 treated L1210 cells to control 305 
cells in late G2 (last 30 min before G2/M transition), early mitosis (before metaphase-to-anaphase 306 
transition), cytokinesis (after metaphase-to-anaphase transition) and newborn G1 (first 30 min after 307 
abscission of daughter cells). In the presence of the mitotic growth inhibitors, G2 MAR was not 308 
affected, but MAR remained low in cytokinesis and in newborn G1 (Figure 7a). In contrast, cells 309 
treated with 100 nM cycloheximide, a translation inhibitor which at this concentration reduces total 310 
protein synthesis by approximately 50% (Figure 3–figure supplement 1d), did not display similar 311 
cell cycle specificity in growth inhibition (Figure 7a). In addition, mother cell MAR in early mitosis 312 
and daughter cell MAR in early G1 correlated in both control (R
2
=0.42) and RO-3306 (R
2
=0.33) 313 
treated cells (Figure 7-figure supplement 1). 1NM-PP1 mediated inhibition of CDK1 in the DT40 314 
CDK1as cell line also resulted in reduced growth during cytokinesis and in daughter cells (Figure 315 
7b).  316 
We speculated that the daughter cell growth inhibition is a consequence of growth 317 
reduction in mother cell mitosis. To validate that mitotic growth is needed to promote daughter cell 318 
growth, we synchronized L1210 cells to G2 phase, released them back to cell cycle in the presence 319 
or absence of mitotic growth inhibitions, and carried out daughter cell growth measurements (see 320 
Figure 7–figure supplement 2a for workflow). First, we measured single-cell MAR using a serial 321 
SMR, which measures MAR over a 15-30 min window (Calistri et al., 2018; Cermak et al., 2016) 322 
(Figure 7–figure supplement 2b). We identified the newborn G1 cells based on their smaller mass 323 
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and quantified their MAR (Figure 7–figure supplement 2c). In addition, we quantified protein 324 
synthesis rates of G1 daughter cells, as identified through DNA staining, and also measured long-325 
term proliferation of the cells. Following mitotic growth inhibitions, either by temporary mitotic 326 
arrest (4 h STLC treatment) or by partial CDK1 inhibition, newborn cells displayed significantly 327 
reduced MAR and protein synthesis rates (Figure 7c,d; Figure 7–figure supplement 3). We then 328 
repeated the daughter cell protein synthesis assays in 4E-BP1 knockdown cells after the mother 329 
cells had progressed through mitosis in the presence or absence of CDK1 inhibition. 4E-BP1 330 
knockdown partly rescued the daughter cell protein synthesis rates that were reduced by CDK1 331 
inhibition (Figure 7e). Thus, 4E-BP1 mediates mitotic protein synthesis of CDK1 (Figure 6), and 332 
this may also affect daughter cell protein synthesis. However, we cannot fully exclude the 333 
possibility that daughter cell growth is affected by some other effects of partial CDK1 inhibition, 334 
such as chromosome missegregation, which could consequently reduce daughter cell growth 335 
independently of mitotic growth. The protein synthesis rate and long-term proliferation rate of the 336 
daughter cells recovered over time (Figure 7e,f), suggesting that mitotic growth inhibitions do not 337 
permanently affect cell viability. 338 
 339 
 340 
Discussion 341 
 342 
We show that animal cells grow approximately 10% of their total mass during M-phase (Figure 1), 343 
indicating that the growth during M-phase is comparable to interphase when the short duration of 344 
M-phase is taken into consideration. This contradicts the classical dogma that growth takes place 345 
primarily during interphase and not during M-phase. Our single-cell measurements show that mass 346 
accumulation behavior during mitosis is dynamic (Figure 2), dependent on mitotic stage (Figure 5), 347 
conserved across a variety of animal cell types grown in suspension (Figure 2) and reflected in 348 
protein synthesis rates (Figure 3). Importantly, growth is only stopped for a short duration in 349 
mitosis, as cells approach the metaphase-to-anaphase transition, and growth recovers in late 350 
cytokinesis after anaphase. Most studies on translation and growth signaling during mitosis use cell 351 
population based experimental approaches that require population enrichment for mitotic cells. This 352 
is commonly achieved by mitotic blockades, which result in growth inhibition (Figure 4). 353 
Alternatively, mitotic cells can be collected with mitotic shake-off. However, this only enriches for 354 
the small subset of mitotic cells that are temporarily not growing (i.e. metaphase and anaphase 355 
cells). Thus, many of the controversial reports regarding translational control during mitosis can be 356 
explained by experimental approaches. 357 
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Conceptually, the tight and conserved coordination between growth rates and mitotic 358 
stages suggests that mitotic growth control is important for cell division. It has been thought that 359 
prioritization of energy away from the ATP consuming macromolecule synthesis and towards 360 
mechanical reorganization of the cell could explain the reduction in mitotic protein synthesis rates 361 
(Kronja and Orr-Weaver, 2011; Sivan and Elroy-Stein, 2008; White-Gilbertson et al., 2009). 362 
Consistent with this hypothesis, we show that growth is stopped when the physical separation of 363 
daughter cells takes place (Figure 2). Yet, there is no direct evidence that cell division would 364 
increase the energetic needs of a cell to a point where growth could not persist, and the inhibition of 365 
growth may therefore be due to other reasons. For example, the inhibition of growth may protect 366 
cells from harmfully excessive cell growth during prolonged mitosis (Miettinen and Bjorklund, 367 
2016; Miettinen et al., 2017; Neurohr et al., 2019).  368 
It has also been proposed that growth, and especially protein synthesis, are required 369 
during mitosis. A complete growth inhibition for the duration of M-phase would result in loss of 370 
short-lived proteins needed for mitosis and cytokinesis (White-Gilbertson et al., 2009). 371 
Consistently, we observe that growth is not inhibited during prophase or late cytokinesis, suggesting 372 
that short-lived proteins, such as survivin (White-Gilbertson et al., 2009), can be produced 373 
immediately prior to and after anaphase. Future studies examining cellular energy production and 374 
mapping the levels of short-lived proteins in different mitotic stages will help elucidate why cells 375 
display such a dynamic growth behavior in mitosis. 376 
Mechanistically, we found that CDK1 promotes mitotic mass accumulation and 377 
protein synthesis, and this is at least partly mediated by 4E-BP1 (Figure 6). Our results are 378 
consistent with previously reported interactions between CDK1 and the translational machinery 379 
(Heesom et al., 2001; Shuda et al., 2015; Smith and Proud, 2008). Importantly, our results do not 380 
exclude the existence of other CDK1 dependent or independent mechanisms regulating mitotic 381 
growth. Indeed, CDK1 remains active until metaphase-to-anaphase transition (Gavet and Pines, 382 
2010), whereas mass accumulation rates begin to decay in late prometaphase and metaphase, 383 
indicating that CDK1 alone cannot fully explain the observed mass accumulation dynamics.  384 
Mitotic growth may be dependent on the time that cells have spent in mitosis, as 385 
growth can be limited by the reduced chromatin accessibility and consequently reduced 386 
transcription. This is consistent with the gradual growth reduction we observe during mitotic arrests 387 
(Figure 4). However, considering the long half-life of most mRNAs (Schwanhausser et al., 2011), 388 
and the observations that mRNA levels do not decline during mitosis (Novais-Cruz et al., 2018; 389 
Tanenbaum et al., 2015), limited chromatin accessibility does not explain why protein synthesis 390 
would be reduced in the absence of mitotic arrests. Furthermore, our results also show that normal 391 
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mitotic progression results in more radical reduction in mass accumulation than what is observed in 392 
prometaphase arrested cells (Figure 5), indicating that there are also other mechanism(s) that 393 
radically reduce mass accumulation around metaphase-to-anaphase transition. 394 
Cell mass accumulation reflects the flux of components, such as nutrients, in and out 395 
of the cell. Because we observe that mass accumulation fully stops during anaphase, or even 396 
becomes negative in some cell types, the mechanism(s) controlling mass accumulation around 397 
metaphase-to-anaphase transition must either block the cells from taking up nutrients or even expel 398 
cellular components. Yet, this does not necessarily mean that protein synthesis comes to a complete 399 
stop, as cells can maintain translation even in the absence of nutrient uptake by degrading proteins 400 
and recycling the components (Son et al., 2015b). In fact, prolonged mitotic arrests resulted in near 401 
zero mass accumulation although ~25% of the protein synthesis rate persisted (Figure 4). We 402 
therefore hypothesize that around metaphase-to-anaphase transition, where the anaphase-promoting 403 
complex drives protein degradation, cells largely stop nutrient uptake but maintain low level of 404 
protein synthesis by recycling amino acids. 405 
We also observed that reducing CDK1 activity results in reduced growth in daughter 406 
cells (Figure 7). This may be explained by CDK1-driven translation of growth components during 407 
mitosis, such as ribosomal proteins, that are required to “jump-start” growth in the newborn cells. 408 
Consistently, several studies have suggested that transcription and translation of growth-related 409 
genes are prioritized during mitosis (Aviner et al., 2017; Palozola et al., 2017; Park et al., 2016). 410 
These results imply that CDK1 does not only coordinate cell division, but also optimizes mitotic 411 
translation to promote immediate daughter cell growth. However, it should be noted that the active 412 
mitotic translation of growth promoting components remains controversial (Stumpf et al., 2013; 413 
Tanenbaum et al., 2015), CDK1 inhibition may reduce daughter cell growth independently of 414 
mitotic growth, and the physiological significance of mitotic translational control in vivo remains 415 
unexplored.  416 
Finally, our observations that mitotic arrests block cell growth have implications for 417 
antimitotic cancer chemotherapy. We observed that the vinca alkaloids Vincristine and Vinblastine, 418 
both commonly used to treat lymphomas, stop cell growth when used in concentrations lower than 419 
those measured in patient plasma (Florian and Mitchison, 2016). This mitotic growth arrest may 420 
contribute to the induction of mitotic catastrophe and the efficacy of antimitotic chemotherapies.  421 
  422 
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Materials and methods 423 
 424 
Key Resources Table 
    
Reagent type 
(species) or resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
cell line (M. musculus) L1210 ATCC 
Cat#CCL-219; 
RRID:CVCL_0382 
  
cell line (M. musculus) L1210 - FUCCI Other   
Generated in a 
previous study (Son et 
al., 2012, Nature 
Methods), cells 
originate from ATCC 
(Cat#CCL-219). 
cell line (M. musculus) L1210 - ECACC ECACC Cat#87092804   
cell line (M. musculus) Fl5.12 Other   
Kindly provided by 
laboratory of Prof. 
Matthew Vander 
Heiden from MIT 
cell line (M. musculus) BaF3 
RIKEN 
BioResource 
Center 
Cat#RCB4476   
cell line (G. gallus) DT40-CDK1as Other   
Kindly provided by 
laboratory of Prof. Bill 
Earnshaw from 
University of Edinburgh 
cell line (H.sapiens) S-HeLa Other   
Kindly provided by 
laboratory of Kevin 
Elias from Brigham And 
Women's Hospital 
transfected construct (M. 
musculus) 
Scrambled shRNA VectorBuilder 
Cat#LVS(VB151023
-10034) 
Refers to a lentiviral 
construct used to 
transfect & express the 
indicated shRNA.  
transfected construct (M. 
musculus) 
4E-BP1 shRNA #1 VectorBuilder 
Cat#LVS(VB181217
-1124dqm)-C 
Refers to a lentiviral 
construct used to 
transfect & express the 
indicated shRNA.  
transfected construct (M. 
musculus) 
4E-BP1 shRNA #2 VectorBuilder 
Cat#LVS(VB181217
-1125ypy)-C 
Refers to a lentiviral 
construct used to 
transfect & express the 
indicated shRNA.  
biological sample 
(H.sapiens) 
Unpurified buffy 
coat for isolation of 
T-cells 
Research Blood 
Components 
NA   
antibody 
Phospho-Histone 
H3 (Ser10) (D2C8) 
XP Rabbit 
monoclonal Ab 
(Alexa Fluor 647 
Conjugate) 
Cell Signaling 
Technology 
Cat#3458; RRID: 
AB_10694086 
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
Phospho-Histone 
H3 (Ser10) (D2C8) 
XP Rabbit 
monoclonal Ab 
(Alexa Fluor 488 
Conjugate) 
Cell Signaling 
Technology 
Cat#3465; RRID: 
AB_10695860 
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
Cyclin B1 (V152) 
Mouse monoclonal 
Ab (Alexa Fluor 488 
Conjugate) 
Cell Signaling 
Technology 
Cat#4112; RRID: 
AB_491024 
Dilution 1/50 in PBS 
supplemented with 5 % 
BSA 
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antibody 
Phospho-4E-BP1 
(Thr37/46) (236B4) 
Rabbit monoclonal 
Ab (PE Conjugate) 
Cell Signaling 
Technology 
Cat#7547; RRID: 
AB_10949897 
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
Phospho-S6 
Ribosomal Protein 
(Ser235/236) 
(D57.2.2E) XP 
Rabbit monoclonal 
Ab (Alexa Fluor 647 
Conjugate) 
Cell Signaling 
Technology 
Cat#4851; RRID: 
AB_10695457 
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
Rabbit (DA1E) 
monoclonal Ab IgG 
XP Isotype Control 
(PE Conjugate) 
Cell Signaling 
Technology 
Cat#5742; RRID: 
AB_10694219 
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
α-Tubulin (11H10) 
Rabbit monoclonal 
Ab (Alexa Fluor 488 
Conjugate) 
Cell Signaling 
Technology 
Cat#5063; RRID: 
AB_10694858 
Dilution 1/200 in PBS 
supplemented with 5 % 
BSA 
antibody 
Cyclin A Mouse 
monoclonal Ab (H-
3) (FITC Conjugate) 
Santa Cruz 
Biotechnology 
Cat#sc-271645; 
RRID: 
AB_10707658 
Dilution 1/25 in PBS 
supplemented with 5 % 
BSA 
antibody 
4E-BP1 (53H11) 
Rabbit monoclonal 
Ab (PE Conjugate) 
Cell Signaling 
Technology 
Cat#34470 
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
Phospho-4EBP1 
(Thr37, Thr46) 
Rabbit monoclonal 
Ab (4EB1T37T46-
A5)  
Thermo Fisher 
Scientific  
Cat#MA5-27999; 
RRID: 
AB_2745012  
Dilution 1/100 in PBS 
supplemented with 5 % 
BSA 
antibody 
Goat polyclonal 
anti-Rabbit IgG 
(H+L) Cross-
Adsorbed 
Secondary Antibody 
(Alexa Fluor 568 
Conjugate)  
Thermo Fisher 
Scientific  
Cat#A-11011; 
RRID: AB_143157  
Dilution 1/1000 in PBS 
supplemented with 5 % 
BSA 
commercial assay or kit 
Click-iT Plus OPP 
Alexa Fluor 594 
Protein Synthesis 
Assay Kit 
Thermo Fisher 
Scientific 
Cat#C10457   
commercial assay or kit T-cell isolation kit Miltenyi Biotec Cat#130-096-495   
commercial assay or kit 
Lambda Protein 
Phosphatase 
New England 
Biolabs 
Cat#P0753S   
chemical compound, 
drug 
O-propargyl-
puromycin (OPP) 
Jena Bioscience 
Cat#NU-931-5; 
CAS:1416561-90-4 
  
chemical compound, 
drug 
S-trityl-l-cysteine 
(STLC) 
Sigma-Aldrich 
Cat#164739; 
CAS:2799-07-7 
  
chemical compound, 
drug 
Nocodazole  Sigma-Aldrich 
Cat#M1404; 
CAS:31430-18-9 
  
chemical compound, 
drug 
MG132 Sigma-Aldrich 
Cat#474787; 
CAS:133407-82-6 
  
chemical compound, 
drug 
proTAME 
Thermo Fisher 
Scientific 
Cat#I44001M; 
CAS:1362911-19-0 
  
chemical compound, 
drug 
Vinblastine 
Cayman 
Chemical 
Cat#11762; 
CAS:143-67-9 
  
chemical compound, 
drug 
Vincristine 
Cayman 
Chemical 
Cat#11764; 
CAS:2068-78-2 
  
chemical compound, 
drug 
TORIN-1 
Tocris 
Bioscience 
Cat#4247; CAS: 
1222998-36-8 
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chemical compound, 
drug 
RO-3306 
Cayman 
Chemical 
Cat#15149; 
CAS:872573-93-8 
We observed the 
chemical loses its 
activity within a month 
when stored in -20ºC. 
All experiments were 
done using a stock 
under 2 weeks old.  
chemical compound, 
drug 
OTSSP167 (OTS) 
Cayman 
Chemical 
Cat#16873; 
CAS:1431698-10-0 
  
chemical compound, 
drug 
1NM-PP1 Sigma-Aldrich 
Cat#529581; 
CAS:221244-14-0 
  
chemical compound, 
drug 
4EGI-1 
Cayman 
Chemical 
Cat#15362; 
CAS:315706-13-9 
  
chemical compound, 
drug 
Cycloheximide 
(CHX) 
Cayman 
Chemical 
Cat#14126; 
CAS:66-81-9 
  
chemical compound, 
drug 
Defactinib 
Cayman 
Chemical 
Cat#17737; 
CAS:1073154-85-4 
  
chemical compound, 
drug 
PF-3758309 
Cayman 
Chemical 
Cat#19186; 
CAS:898044-15-0 
  
chemical compound, 
drug 
Nintedanib 
Cayman 
Chemical 
Cat#11022; 
CAS:656247-17-5 
  
chemical compound, 
drug 
SNS-032  
Cayman 
Chemical 
Cat#17904; 
CAS:345627-80-7 
  
chemical compound, 
drug 
Tozasertib 
Cayman 
Chemical 
Cat#13600; 
CAS:639089-54-6 
Alternative Names: MK 
0457, VX 680 
chemical compound, 
drug 
GSK 626616 R&D Systems 
Cat#6638; 
CAS:1025821-33-3 
  
chemical compound, 
drug 
EIPA Sigma-Aldrich 
Cat#A3085; 
CAS:1154-25-2  
  
chemical compound, 
drug 
(-)-Blebbistatin Sigma-Aldrich 
Cat#B0560; 
CAS:856925-71-8  
  
software, algorithm MATLAB R2014b MathWorks   
Used to analyze the 
SMR raw data and 
generate data plots.  
software, algorithm OriginPro 2019 OriginLab   
Used to perform 
statistical analyses and 
generate data plots.  
software, algorithm 
Mass accumulation 
rate analysis code 
This paper   
Used to analyze the 
SMR data. Code can 
be found attached to 
this manuscript. 
 425 
Cell lines, primary cells and culture conditions 426 
L1210 cells were obtained directly from ATCC, with the exception of L1210 cells 427 
shown in Figure 2–figure supplement 2b, which were obtained from ECACC. L1210 cells 428 
expressing the FUCCI cell cycle sensor were generated in a previous study (Son et al., 2012) using 429 
ATCC originating cells. The BaF3 cells were originally obtained from RIKEN BioResource Center 430 
and engineered to express BCR-ABL in a previous study (Stevens et al., 2016). S-HeLa cell line 431 
was a gracious gift from Dr Elias. FL5.12 cell line was a gracious gift from Dr Vander Heiden. All 432 
DT40 cell experiments were carried out using DT40 CDK1as cell line, which was a gracious gift 433 
from Dr Samejima and Dr Earnshaw. The DT40 CDK1as cells have had their CDK1 replaced with 434 
Xenopus laevis CDK1 with a F80G mutation, as detailed in (Gibcus et al., 2018), to sensitize the 435 
CDK1 to inhibition by 1NM-PP1. Note that the CDK1as cell line is protected by MTA and the 436 
rights to this cell line belong to Prof Earnshaw and the University of Edinburgh. All cell lines tested 437 
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negative for mycoplasma. Cell line identity was validated by vendors and the identity of L1210 438 
cells from ATCC was further validated using RNA-seq data.  439 
The L1210 cells basic experimental and culture conditions were in 2 mM L-glutamine 440 
and 11 mM glucose containing RPMI (Thermo Fisher Scientific, #11835030) supplemented with 441 
10% FBS (Sigma-Aldrich), 1 mM sodium pyruvate (Thermo Fisher Scientific), 20 mM HEPES 442 
(Thermo Fisher Scientific) and antibiotic/antimycotic (Thermo Fisher Scientific). In Figure 2–figure 443 
supplement 2a, where L1210 cells were grown under different nutrient conditions, the media was 444 
kept otherwise identical except for 4% FBS and indicated concentrations of glucose (Sigma-445 
Aldrich) or galactose (Sigma-Aldrich). The L1210 experimental conditions also included 10 nM 446 
TMRE in the media, which did not affect cell growth. 447 
BaF3, FL5.12 and DT40 CDK1as cells were grown in media identical to L1210 cells, 448 
with the exceptions that FL5.12 cell media was supplemented with 10 ng/ml IL-3 (R&D Systems) 449 
and DT40 cell media was supplemented with 3% chicken serum (Sigma-Aldrich). S-HeLa cells 450 
were grown in DMEM (Thermo Fisher Scientific) containing 10% FBS (Sigma-Aldrich), 1 mM 451 
sodium pyruvate (Thermo Fisher Scientific), 20 mM HEPES (Thermo Fisher Scientific) and 452 
antibiotic/antimycotic (Thermo Fisher Scientific). 453 
Human peripheral blood mononuclear cells (PBMCs), including T-cells, were isolated 454 
from unpurified buffy coat (Research Blood Components) and activated as described previously 455 
(Cermak et al., 2016). Briefly, PBMCs isolation was carried out using Ficoll-Paque Plus density 456 
gradient (GE) according to the manufacturer’s recommendations. After isolation of the PBMC 457 
layer, the cells were subjected to red blood cell lysis using ACK lysis buffer (Thermo Fisher 458 
Scientific). The PBMCs were then washed three times and either frozen or used for isolation of 459 
specific T-cell subsets. The T-cell data shown in this paper is derived from both frozen and non-460 
frozen samples obtained from two independent blood samples. Primary T-cells were isolated using 461 
Naive CD8+ or CD3+ T Cell Isolation Kits (Miltenyi Biotec) according to supplier’s instructions. 462 
The primary T-cells were activated on an anti-human CD3 (BioLegend) coated cell culture plate in 463 
identical to L1210 culture media, with the exception that the media was supplemented with 10 µM 464 
2-mercaptoethanol, 100 U/ml IL-2 (R&D Systems) and 2 µg/ml anti-human CD28 (BioLegend). 465 
The same media was used for SMR experiments. After activation, cells were left undisturbed for 24 466 
h before SMR experiments, and the activation was validated by monitoring cell number and volume 467 
changes using Coulter Counter (Beckman Coulter). 468 
The shRNA expressing L1210 cells were generated as in (Kang et al., 2019). L1210 469 
cells (obtained from ATCC) were transfected using mammalian shRNA knockdown lentiviral 470 
vectors obtained from VectorBuilder Inc. Each construct contained an shRNA sequence under a U6 471 
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promoter, as well as EGFP and Puro linked by T2A for selection. Full construct details can be 472 
found online at VectorBuilder.com (Vector IDs: VB190401-1106ebw, VB190401-1107bty and 473 
VB190401-1108sfm) 474 
 475 
Control shRNA target sequence: CCTAAGGTTAAGTCGCCCTCG 476 
4E-BP1 shRNA #1 target sequence: ATTATCTATGACCGGAAATTT (location: 233-253, CDS) 477 
4E-BP1 shRNA #2 target sequence: CCAGTGTTTATGGTGTGATTT (location: 912-932, 3’UTR) 478 
 479 
Transfection was carried out using 4 rounds of spinoculation. In each round, 1.5 × 105 L1210 cells 480 
were mixed with 10 µg/ml Polybrene (EMD Millipore) and approximately 1 × 106 transducing units 481 
of lentivirus. The mixture was centrifuged at 800 g for 60 min at 25 °C, and the cells were moved to 482 
normal culture media. This procedure was repeated every 12 h for a total of 4 times. 24 h after the 483 
last round of transfection selection was started using 10 µg/ml puromycin (Sigma-Aldrich). After 5 484 
days of selection the shRNA and EGFP expressing subpopulation was sorted out using BD FACS 485 
Aria. shRNA knockdown efficiency was validated by immunostaining 4E-BP1 and quantifying the 486 
staining levels using FACS (antibody staining details are below, Figure 6-figure supplement 4a,b).  487 
 488 
SMR device setup and experimental details 489 
The SMR chips were fabricated as previously described (Cermak et al., 2016; Son et 490 
al., 2015a; Son et al., 2012) by CEA-LETI, Grenoble, France. The device setup and experimental 491 
details were similar to those described previously (Cermak et al., 2016; Son et al., 2015a; Son et al., 492 
2012). Briefly, a piezo-ceramic placed under the device vibrates the cantilever in its second flexural 493 
bending mode resonant frequency, which is typically ~1.1 MHz. The resonant frequency was 494 
monitored using piezo-resisters embedded at the base of the cantilever. A digital control platform 495 
was used to actuate the cantilever in a direct feedback mode, where an actuating signal is generated 496 
by amplifying and delaying the detected motion signal from the cantilever. Utilizing the feedback 497 
mode with a data rate of ~3000 Hz, our SMR measurement bandwidth was fixed to ~ 1500 Hz, 498 
which was adequate to capture fast modulating frequency signal resulting from a cell transit through 499 
the cantilever.  500 
SMR device was operated at a fixed temperature of 37°C, by mounting the SMR chip 501 
on a copper clamp that was connected to a circulating, temperature-controlled water bath (Julabo). 502 
Fluid flow was controlled by pressure difference across the SMR input ports. Each input port was 503 
connected to a reservoir of normal cell culture media that was pressurized with 5% CO2, 21% O2 504 
(Airgas) to maintain stable pH. The amount of pressure applied to each vial were controlled using 505 
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electronic pressure regulators (Proportion Air QPV1) and the applied pressure difference across the 506 
channel was set to achieve a typical flow rate of ~2 nL/s to minimize the shear stress of cells 507 
growing within the SMR. This resulted in a typical ~300 ms transit time through the cantilever. 508 
Both the absolute pressure and flow direction were controlled using a custom software (LabVIEW 509 
2012 and LabVIEW 2016). The software controls the pressure levels, and consequently the flow 510 
direction and speed, in real-time, and is automated to quickly respond to a change in resonant 511 
frequency signal. For example, a set of pressures are applied to flow a cell through the cantilever 512 
(Figure 1–figure supplement 1a, left #1). The resonant frequency change caused by cell transit 513 
through the cantilever automatically stops the flow (Figure 1–figure supplement 1a, left #2). Flow is 514 
maintained at zero for desired amount of time (~50 s), after which the pressures are changed to 515 
reverse the flow direction (Figure 1–figure supplement 1a, left #3). See Figure 1–figure supplement 516 
1 for the detailed steps of the fluid control and consequent cell movement. 517 
For monitoring morphology changes during mitosis and measuring FUCCI cell cycle 518 
reporter intensity, we utilized an on-chip imaging system described previously (Son et al., 2012). 519 
Briefly, a modular Nikon microscope equipped with a Nikon LU plan ELWD 50x/0.55 objective, a 520 
Lumencor Spectra X light engine and an 8 mm Voltage Output Type photomultiplier tube (Edmund 521 
Optics) or a monochrome camera (BFS-U3-13Y3M-C, FLIR). As a cell passed through the SMR 522 
cantilever, the change in the resonance frequency was used as a trigger to turn on illumination and 523 
measure the FUCCI reporter fluorescence. On-chip cell imaging was done as in (Calistri et al., 524 
2018). 525 
 526 
Data acquisition & processing 527 
The motion of the cantilever and thus the resonant frequency of the SMR was 528 
measured by a digital control platform described previously (Cermak et al., 2016). The measured 529 
signal in digital platform was fed into custom LabVIEW code that records the signal while cell is in 530 
transit. Recorded frequency was then post-processed by custom MATLAB code, as described 531 
previously (Cermak et al., 2016). Briefly, the code locates two local minima in frequency peaks, fits 532 
a fourth order polynomial to the raw data, and the minimum resonance frequency values are 533 
extracted from the fittings. The average of these two resonance frequency minima measured in Hz 534 
was then transformed in to picograms by calibrating the measurements using monodisperse 535 
polystyrene beads (Thermo Fisher Scientific, Duke Standards) with a known buoyant mass. No 536 
frequency peak exclusion was performed, except in an extremely rare event where two daughter 537 
cells separate inside the cantilever during transit. 538 
 539 
21 
 
Assigning cell cycle transitions to buoyant mass traces 540 
We identified three distinct cell cycle transition points: mitotic entry (i.e. G2/M 541 
transition), metaphase-to-anaphase transition (i.e. M/A transition) and daughter cell abscission 542 
(Figure 1–figure supplement 2). We defined M-phase as the sum of mitosis and cytokinesis, starting 543 
at mitotic entry and ending at daughter cell abscission. We identified metaphase-to-anaphase 544 
transition using the mAG-Geminin signal of the FUCCI cell cycle reporter, which is degraded at 545 
metaphase-to-anaphase transition (Figure 1–figure supplement 2c), and using on-chip brightfield 546 
imaging, where we identified the metaphase-to-anaphase transition as the last timepoint of cell 547 
being round. These signals always coincided with two biophysical signals measured by SMR, a 548 
drop in node deviation signal (an acoustic signal corresponding to cell shape and stiffness) and a 549 
momentary reduction in buoyant mass trace (Figure 1–figure supplement 2b), both partly due to cell 550 
elongation in anaphase (Kang et al., 2019). These elongation dependent signals are applicable to all 551 
cell types studied here and this was validated by on-chip imaging, allowing us to designate 552 
metaphase-to-anaphase transition for all cells. 553 
The daughter abscission was assigned for all cells based on the approximately 50% 554 
loss of buoyant mass within 2 min. Cytokinesis was defined as the time between metaphase-to-555 
anaphase transition and daughter cell abscission. G1 was defined to start immediately following cell 556 
abscission.  557 
Detection of mitotic entry (G2/M transition) for L1210 cells was carried out using 558 
biophysical parameters. First, we have previously shown that node deviation starts to decrease 559 
following mitotic entry (Kang et al., 2019) (Figure 1–figure supplement 2b), allowing us to locate 560 
mitotic entry for L1210 traces. The timing of the assigned mitotic entry (30 min prior to metaphase-561 
to-anaphase transition) also matched with previously analyzed mitotic entry point based on single-562 
cell volume measurements (Son et al., 2015a; Zlotek-Zlotkiewicz et al., 2015). Similar node 563 
deviation based assignment of approximate mitotic entry was also done for other cell types, 564 
whenever node deviation changes were observable. We also estimated the approximate mitotic 565 
entry by comparing the whole cell cycle duration to that of L1210 cells. When cell cycle durations 566 
were similar, we utilized the same timing of mitotic entry (30 min prior to metaphase-to-anaphase 567 
transition) for the other cell types, which was also consistent with the timing of mitotic entry 568 
observed by node deviation measurements. While this is an approximation, it is consistent with the 569 
notion that the duration of mitosis does not vary drastically cell-to-cell (Araujo et al., 2016). For 570 
chemical perturbations that prolonged early mitosis, the approximate mitotic entry is separately 571 
indicated in the figures (for example, arrows in Figure 6d). 572 
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Approximate duration of L1210 cell metaphase was assigned using the G2/M and 573 
metaphase-to-anaphase transitions together with previous characterization of the relative durations 574 
of different mitotic stages in L1210 cells (Son et al., 2015a). The duration of cell elongation (i.e. 575 
anaphase) was quantified for L1210 cells previously (12 min) (Kang et al., 2019) and the duration 576 
was approximated for other cell types using on-chip imaging. 577 
 578 
Analyzing mass accumulation rate (MAR) and MAR/mass 579 
To quantify average MAR/mass of for late G2, early mitosis, cytokinesis and newborn 580 
G1, as seen for example in Figure 7a, a single linear fit was made to the buoyant mass traces for 581 
each indicated cell cycle stage and the slope of the fit represents the MAR (Figure 2–figure 582 
supplement 1a). To minimize the error in the length of fitted segment, data points were linearly 583 
interpolated from the buoyant mass trace to accurately pinpoint the beginning and the end of the 584 
fitted segments. Then, each slope of the linear fits (MAR) was divided by the average mass during 585 
the fitting period to obtain MAR/mass. 586 
To quantify MAR/mass dynamics within mitotic stages, as seen for example in Figure 587 
2a, we quantified the slope and average mass during each 10 min segments in the buoyant mass 588 
traces (Figure 2–figure supplement 1b). The 10 min segments were separated by 5 min. The 10 min 589 
segments were separately fitted a linear line, and each slope of the fitted line represents MAR 590 
(Figure 2–figure supplement 1c). Then MAR of each 10 min segment was divided by the average 591 
mass within that 10 min segment to calculate MAR/mass (Figure 2–figure supplement 1d). To 592 
minimize the error in the length of fitted segment, data points were linearly interpolated from the 593 
buoyant mass trace to increase number of data points. The MAR/mass dynamics shown in Figure 5; 594 
Figure 5–figure supplement 1; Figure 5–figure supplement 2 were processed similarly but the 595 
length of each segment and separation between each segment were reduced to 4 min and 2 min, 596 
respectively. When showing MAR/mass dynamics of individual cells (Figure 2d; Figure 2-figure 597 
supplement 1c,d; Figure 5-figure supplement 2a), buoyant mass traces were filtered using a moving 598 
average covering a 10 min window of data.  599 
To correct for the cell elongation induced bias in buoyant mass measurement during 600 
cytokinesis, we performed a data correction as shown before (Kang et al., 2019). Briefly, the change 601 
in cell mass distribution (cell elongation) reduces the resonance frequency shift of the SMR, in a 602 
manner that is dependent on cell geometry. Using on-chip imaging, cell mass & volume information, 603 
we estimated the cell geometry to be i) spherical before elongation, ii) overlapping spheres during 604 
anaphase, and iii) spherical doublets after elongation is over (Figure 1-figure supplement 1d,e). 605 
With this information we can calculate the estimated extent of the measurement bias. The details 606 
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can be found in the (Kang et al., 2019) and in the MATLAB code attached to the supplements. The 607 
calculated extent of the measurement bias during L1210 cell cytokinesis can be seen in Figure 1–608 
Figure supplement 1d and in Figure 2–Figure supplement 1d. 609 
 610 
Chemical perturbations 611 
All SMR experiments with chemical perturbations of cell growth or cell cycle, apart 612 
from serial SMR experiments, were carried out by diluting the chemicals directly in to the media 613 
within SMR. Untreated cells were then loaded to the SMR for growth monitoring, so that in a 614 
typical experiment the cell was exposed to the chemical for at least two hours before entering 615 
mitosis. Experiments with chemical inhibitors only lasted through one cell division, so that 616 
exposure to the chemicals was always started in interphase, approximately 1-4 h prior to mitosis. 617 
Thus, the n indicated for chemical treatments always reflects separate experiments. Control 618 
experiments were always carried out between experiments with chemical perturbations to assure 619 
that control cell growth rates were reproducible. Note that the control L1210 cell data is 620 
accumulated over several years and the growth behavior was reproducible also between different 621 
SMR devices (Figure 2-figure supplement 2c).  622 
For serial SMR experiments where cells were arrested to mitosis using STLC, cells 623 
were loaded in to the serial SMR in normal culture media immediately after STLC wash off. For 624 
serial SMR experiments where cells were treated with RO-3306, cells were loaded in to the serial 625 
SMR in 1 µM RO-3306 containing culture media immediately after release from G2 arrest. In 626 
Figure 4c, mitotic arrests were obtained by treating unsynchronized L1210 cells with 5 µM STLC, 1 627 
µg/ml Nocodazole, 2 µM MG132 or 20 µM proTAME.  628 
Importantly, we observed that RO-3306 stock stored in -20°C in DMSO was not 629 
stable over several months and we therefore carried out all experiments using RO-3306 that was 630 
prepared within one week of the experiment. 631 
 632 
Cell cycle synchronizations 633 
L1210 cells were synchronized to G2 using a double thymidine block followed by a 634 
RO3306 mediated G2 arrest. L1210 cells in confluency of 4*10
5
 cells were first treated with 2 mM 635 
Thymidine for 15 h, then washed with PBS and moved to normal culture conditions to release from 636 
G1/S arrest. After 6 h, 2 mM Thymidine was added for 6 h. Cells were again washed with PBS and 637 
moved to normal culture conditions for 3 h, after which 5 µM RO-3306 was added. 7 h later cells 638 
were arrested in G2 (Figure 3a). Cells were then washed with PBS and moved to normal culture 639 
conditions (unless otherwise stated) to allow cells to uniformly progress through mitosis. Note 640 
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while most cells enter mitosis soon after release from G2 arrest, some cells fail to exit G2. The 641 
release from G2 arrest was considered as time zero in protein synthesis, serial SMR and 642 
proliferation experiments. 643 
When cells were temporarily arrested in mitosis (Figure 7c,d,f), cells were first 644 
synchronized to G2, then released in to 5 µM STLC. 4 h later the cells were washed twice with 645 
media and replaced in to normal cell culture conditions. The release from STLC mediated mitotic 646 
arrest was considered as time zero in protein synthesis, serial SMR and proliferation experiments. 647 
 648 
Protein synthesis rate sample preparation 649 
Protein synthesis rates were quantified using the Click-iT Plus OPP Alexa Fluor 594 650 
Protein Synthesis Assay Kit (Thermo Fisher Scientific) together with antibody staining specific for 651 
different mitotic stages. For each replicate approximately 3*10
6
 cells were treated with 20 µM OPP 652 
for 10 min under normal culture conditions. The OPP accumulation was stopped by mixing the cells 653 
with ice cold PBS, after which the cells were quickly washed with ice cold PBS and then fixed with 654 
formaldehyde for 10 min at room temperature. To reduce the number of cell doublets fixed 655 
together, the fixation was carried out by shaking the cells on vortex in PBS and slowly adding a 656 
corresponding volume of 8% paraformaldehyde to reach a final paraformaldehyde concentration of 657 
4%. Fixative was washed away with PBS and the cells were permeabilized using 0.5% Triton X-658 
1000 in PBS for 10 min at room temperature. The permeabilization solution was washed away with 659 
PBS and cells were incubated in 5% BSA in PBS for 30 min to block non-specific antibody 660 
binding.  661 
Mitotic cells were separated from interphase cells using p-Histone H3 monoclonal 662 
antibody (S10, D2C8, conjugated to Alexa 647, Cell Signaling Technology, #3458S; or S10, D2C8, 663 
conjugated to Alexa 488, Cell Signaling Technology, #3465S). For separation of mitosis in to early 664 
and late mitosis, Cyclin B1 (V152, conjugated to Alexa 488, Cell Signaling Technology, #4112S) 665 
and Cyclin A (H-3, conjugated to FITC, Santa Cruz Biotechnology, #sc-271645 FITC) monoclonal 666 
antibodies were used. All antibody labeling steps were carried out o/n in 4°C in 5% BSA containing 667 
PBS. All antibodies were used at the concentration recommended by supplier. Antibodies were 668 
washed away using 5% BSA in PBS. 669 
The OPP Click-IT reaction was carried out according to manufacturer’s (Thermo 670 
Fisher Scientific) instructions. After OPP conjugation with Alexa Fluor 594 fluorophore, the cells 671 
were washed twice with PBS and DNA was stained for 30 min in RT with 1:2000 dilution of 672 
NuclearMask Blue (#H10325, Thermo Fisher Scientific). Finally, the cells were washed three times 673 
with PBS, mixed in to PBS supplemented with 1% BSA and put on ice until FACS analysis.  674 
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 675 
Protein content and phosphorylation level sample preparation 676 
To analyze the levels of total 4E-BP1 or phosphorylated S6RP and 4E-BP1, 677 
unperturbed cells were prepared using same fixation, permeabilization and blocking protocol as for 678 
protein synthesis assays. The cells were then incubated o/n in 4°C with 4E-BP1 monoclonal 679 
antibody (53H11, Cell Signaling Technology, #34470), p-4E-BP1 monoclonal antibody (Thr37/46, 680 
236B4, conjugated to PE, Cell Signaling Technology, #7547S), p-S6RP monoclonal antibody 681 
(S235/236, D57.2.2E, conjugated to Alexa 647, Cell Signaling Technology, #4851S) or isotype 682 
specific controls (Rabbit mAb IgG, conjugated to PE or Alexa 647, Cell Signaling Technology, 683 
#5742S) in PBS solution containing 5% BSA. All antibodies were used at the concentration 684 
recommended by supplier. For analysis of total 4E-BP1 levels, cells were washed and treated with 2 685 
µg/ml secondary antibody (Goat anti-Rabbit IgG secondary antibody conjugated to Alexa Fluor 686 
568, #A-11011, Thermo Fisher Scientific) for 2 h in RT. Antibodies were washed away using 5% 687 
BSA in PBS and the cells were stained for p-Histone H3 (S10) and DNA, as in protein synthesis 688 
assays. Finally, the cells were washed three times with PBS, mixed in to PBS supplemented with 689 
1% BSA and put on ice until FACS analysis. 690 
 691 
Flow cytometry 692 
FACS based quantifications were done using BD Biosciences flow cytometer LSR II 693 
HTS with excitation lasers at 355nm, 488nm, 561nm and 640nm, and emission filters at 450/50, 694 
530/30, 585/15 and 660/20. See (Figure 3a,c; Figure 3–figure supplement 1a) for DNA and 695 
antibody labeling that were used to separate cell cycle stages. At least 20,000 cells were analyzed 696 
for each replicate so that each analyzed subpopulation contained at least 250 cells, and typically 697 
over 1000 cells. 698 
 699 
Microscopy 700 
For validation of OPP staining, L1210 cells were plated on coverslips coated with 701 
0.1% poly-L-lysine, and prepared using same fixation, permeabilization, blocking, antibody 702 
labeling and DNA staining protocol as for protein synthesis assays. After all staining procedures 703 
were done, the cells were mounted on to microscopy slides in Vectashield mounting medium 704 
(Vector Laboratories). 705 
For examination of phosphorylated 4E-BP1, L1210 cells were plated on coverslips 706 
coated with 0.1% poly-L-lysine, and prepared using same fixation, permeabilization and blocking 707 
protocol as for protein synthesis assays. The cells were then labeled o/n in 4°C with p-4E-BP1 708 
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monoclonal antibody (Thr37/46, 4EB1T37T46-A5, #MA5-27999, Thermo Fisher Scientific). The 709 
following day the cells were washed three times with PBS and then treated with 2 µg/ml secondary 710 
antibody (Goat anti-Rabbit IgG secondary antibody conjugated to Alexa Fluor 568, #A-11011, 711 
Thermo Fisher Scientific) for 2 h, before an o/n labelling in 4°C with α-Tubulin monoclonal 712 
antibody (11H10, conjugated to Alexa Fluor 488, #5063, Cell Signaling Technology). The 713 
following day the cells were washed three times with PBS and DNA was stained for 30 min in RT 714 
with 1:2000 dilution of NuclearMask Blue (#H10325, Thermo Fisher Scientific). The cells were 715 
washed three times with PBS and mounted on to microscopy slides in Vectashield mounting 716 
medium (Vector Laboratories).OPP staining and 4E-BP1 phosphorylation levels were imaged using 717 
DeltaVision wide-field deconvolution microscope using standard filters (DAPI, FITC, TRITC) and 718 
100× objective. After deconvolution using SoftWoRx 7.0.0 software, approximately 3 µm thick 719 
section from the middle of z-slices was merged into a maximum intensity image for visualization. 720 
Cell proliferation rate was analyzed by imaging the cells every 1 h using IncuCyte live 721 
cell analysis imaging system by Sartorius. The relative cell count was then assessed from the phase 722 
images by analyzing the relative confluency in each sample. These values were normalized to the 723 
value at start and hourly average values were plotted together with the standard error of mean 724 
(SEM). Representative images displaying the duration of daughter cell separation (Figure 2c,e) 725 
were obtained in a parallel experiment using IncuCyte live cell analysis imaging system by 726 
Sartorius with 20X objective or using on-chip imaging in the SMR with the imaging setup detailed 727 
in the section ‘SMR device setup and experimental details’. 728 
 729 
Lambda protein phosphatase treatment 730 
 To verify the phospho-specificity of the p-4E-BP1 antibodies, cells were prepared 731 
using same fixation, permeabilization and blocking protocol as detailed above. The cells were first 732 
treated with p-Histone H3 antibody to label mitotic cells and to protect p-Histone H3 sites from 733 
Lambda phosphatase, after which the phosphatase treatment and DNA staining were carried out. 734 
The cells were then treated with 10,000 units/ml of Lambda protein phosphatase in 1X NEBuffer 735 
for protein MetalloPhosphatases that contained 1 mM MnCl2 for 12 h in 30°C, after which cells 736 
were washed twice with PBS. The Lambda phosphatase and the treatment buffer were obtained 737 
from New England BioLabs (#P0753S). Finally, DNA was stained as detailed above and the cells 738 
were analyzed using flow cytometer.  739 
 740 
Combining & normalizing data 741 
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Total mass accumulation for each cell was calculated from the mass accumulation 742 
traces, by assuming that the birth size of the cell was exactly half of the abscission size. Mass 743 
accumulation during mitosis (between G2/M transition and metaphase-to-anaphase transition) and 744 
during cytokinesis (between metaphase-to-anaphase transition and daughter cell abscission) was 745 
then normalized to the calculated total mass accumulation for each cell. MAR/mass traces (i.e., 746 
MAR/mass vs time) from each single cell were aligned to metaphase-to-anaphase transition. We 747 
then linearly interpolated data points from each MAR/mass trace, consequently making the total 748 
number of timepoints for each cell to be 100. Mean and SD were calculated for each timepoint and 749 
plotted as a function of approximate mitotic entry (30 min before metaphase-to-anaphase transition 750 
for most cell types). In Figure 4, where the drug-induced mitotic arrests inhibit us from aligning the 751 
data to metaphase-to-anaphase transition, all data was aligned to approximate mitotic entry using 752 
node deviation and MAR/mass signals. In addition, in Figure 4d, the MAR/mass traces were 753 
smoothed with a moving average filter of length 3. Data smoothing was not done for any other 754 
datasets. In Figures 7a,b, average MAR/mass for each indicated cell cycle stage (late G2, early 755 
mitosis, cytokinesis and early G1) was normalized to control values within that cell cycle stage.  756 
 757 
Statistical information 758 
 All statistical tests carried out, as well as descriptions of error bars and numbers of 759 
replicates, are detailed in the figure legends. All t-tests were two tailed. No replicates were 760 
excluded, except for image analysis, when cells could not be analyzed, as detailed above. No power 761 
analysis was used. Sample size was kept at or above 3 independent replicates, with exact sample 762 
size depending on the experimental setup. Many of the experimental approaches required time-763 
sensitive sample processing, which limited the maximum sample size. In all FACS based assays, 764 
the replicate number refers to independent cell cultures. In all SMR based assays, the replicate 765 
number refers to independent cells measured through mitosis. In SMR based assays, control 766 
samples were grown for multiple generations yielding several replicates in one experiment, whereas 767 
drug treated samples were only grown through one division so that each drug treated replicate 768 
represents a separate experiment. Experiments were repeated at least three times on separate days, 769 
unless otherwise stated in the figure legends.  770 
 The increase in L1210 cell MAR/mass from G2 to early mitosis was quantified by 771 
comparing the highest MAR/mass values observed in G2 and in early mitosis for each cell 772 
separately. The statistical comparison between these two groups was carried out by two-tailed 773 
Student’s t-test.  774 
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Statistical tests were carried out using OriginPro 2019 software. The analysis of 775 
buoyant mass traces and the analysis of images was carried out using MATLAB R2014b. 776 
Visualization of microscopy images was carried out using ImageJ. All figures were compiled using 777 
Adobe Illustrator CC 2018. 778 
 779 
Data and data analysis code availability 780 
All L1210 control buoyant mass measurement shown in Figure 1 and used for 781 
quantification of MAR/mass in Figure 2a can be found in Figure 1–source data 1. This data has not 782 
been corrected for the cell elongation. Data analysis code for correcting the cell elongation bias and 783 
obtaining MAR from the buoyant mass traces can be found attached to this manuscript. 784 
  785 
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Main Figure Legends 994 
 995 
Figure 1: Various animal cell types grow during mitosis and cytokinesis 996 
(a) Left, schematic of a suspended microchannel resonator (SMR). Single-cell buoyant mass is 997 
repeatedly measured as the cell flows back and forth through the vibrating cantilever. Right, at cell 998 
division, one of the daughter cells is randomly selected and monitored, while the other daughter cell 999 
is discarded from the SMR.  1000 
(b) Buoyant mass trace of a single L1210 cell and its progeny over five full generations. The 1001 
interdivision time (~9 h) for cells growing in the SMR and in normal cell culture condition is 1002 
equivalent. Blue arrows indicate the abscissions of daughter cells.  1003 
(c) Overlay of 180 individual L1210 cell buoyant mass traces (transparent orange) and the average 1004 
trace (black) around mitosis. Each mass trace has been normalized so that the typical cell abscission 1005 
mass is 2.  1006 
(d) Mass accumulation in mitosis (before metaphase/anaphase transition, red) and cytokinesis (blue) 1007 
relative to the total mass accumulated during the cell cycle for various animal cell types Total 1008 
relative mass accumulation in M-phase (sum of mitosis and cytokinesis) is indicated on top. Note 1009 
that while the relative mass accumulation in cytokinesis varies between cell types, all cell types 1010 
display similar mass accumulation % in early mitosis. n refers to the number of individual cells 1011 
analyzed. Boxplot line: median, box: interquartile range, whiskers: ±1.5x interquartile range. 1012 
 1013 
Figure 2: Cell mass accumulation persists through prophase, stops as cells approach 1014 
metaphase-to-anaphase transition and recovers during late cytokinesis 1015 
(a) Mass-normalized mass accumulation rate (MAR) of L1210 cells in late G2 and M-phase. G2/M 1016 
and metaphase-to-anaphase transitions are indicated with dashed vertical lines. Typical durations of 1017 
metaphase and cell elongation (singlet to doublet) are indicated in green and light brown areas, 1018 
respectively. n refers to number of individual cells analyzed. 1019 
(b) Quantification of L1210 cell maximal growth rate in late G2 and in mitosis (n=180 cells). P-1020 
values obtained using two-tailed Welch’s t-test. In boxplots, line: median, box: interquartile range, 1021 
whiskers: 5-95%. 1022 
(c) Representative L1210 cell phase contrast (grey) and mAG-hGeminin cell cycle reporter (green) 1023 
images (n=18 cells). Times correspond to (a) and (d). Note that the physical separation of daughter 1024 
cells takes place when cells are not accumulating mass. 1025 
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(d) Examples of individual L1210 mass-normalized MAR traces in late G2, M-phase and early G1. 1026 
Arrows indicate the final abscission of daughter cells, around which mass-normalized MAR is 1027 
indicated with dashed lines. M/A denotes the metaphase-to-anaphase transition, G2/M denotes the 1028 
approximate mitotic entry, both of which are indicated with dashed vertical lines. 1029 
(e) Mass-normalized MAR of indicated cell types along with representative images displaying the 1030 
duration of the physical separation of daughter cells. BaF3 and DT40 cells were imaged separately, 1031 
whereas S-HeLa and CD3+ T cells were imaged on-chip simultaneously with MAR measurements. 1032 
M/A denotes the metaphase-to-anaphase transition, G2/M denotes the approximate mitotic entry, 1033 
both of which are indicated with dashed vertical lines. Solid dark blue lines indicate the mean and 1034 
light blue areas represent ±SD. n refers to number of individual cells analyzed. 1035 
 1036 
Figure 3: Mitotic protein synthesis dynamics are consistent with mass accumulation dynamics 1037 
(a) Top, schematic of the protocol for quantifying mitotic protein synthesis rates using O-propargyl-1038 
puromycin (OPP). G2 synchronization was achieved by double thymidine block followed by RO-1039 
3306 mediated G2 arrest. Bottom, representative FACS scatter plots indicating L2110 cell cycle 1040 
synchrony (n=3 independent experiments). Phospho-Histone H3 (Ser10) was used as a mitotic 1041 
marker.  1042 
(b) Ratio of protein synthesis rate (blue) between mitotic and G2 L1210 cells after release from G2 1043 
arrest. Light green area displays the typical protein synthesis ratio between mitotic and G2 cells in 1044 
the absence of cell cycle synchronization. The relative portion of mitotic cells is shown in orange. 1045 
Each data point represents an individual replicate. (n=3 separate cultures for each timepoint). Time 1046 
of G2 release and the typical time to reach metaphase-to-anaphase transition are indicated with 1047 
dashed vertical lines. 1048 
(c) Representative FACS scatter plot indicating the separation of early (prophase) and late 1049 
(metaphase to telophase) mitotic L1210 cells using Cyclin A antibody staining. 1050 
(d) Protein synthesis rate of G2, early mitotic and late mitotic L1210 cells. (n=6 separate cultures). 1051 
Early and late mitotic cells were separated as shown in (g). P-values obtained using ANOVA 1052 
followed by Tukey’s posthoc test. 1053 
 1054 
Figure 4: Mitotic arrests result in growth inhibition independently of the mechanism of arrest 1055 
(a) Mass-normalized MAR of 5 µM STLC or 1 mg/ml Nocodazole treated L1210 cells in late G2 1056 
and mitosis. Dashed vertical line indicates the approximate mitotic entry. Solid dark lines indicate 1057 
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the mean and light areas represent ±SD. n refers to number of individual cells analyzed. Drug 1058 
treatments started 1-4h prior to mitotic entry and were maintained through the experiment. 1059 
(b) Ratio of protein synthesis rate (blue) between mitotic and G2 L1210 cells after release from G2 1060 
arrest in to 5 µM STLC mediated mitotic arrest. Light green area displays the typical protein 1061 
synthesis ratio between mitotic and G2 cells in the absence of cell cycle synchronization. The 1062 
relative portion of mitotic cells is shown in orange. Each data point represents an individual 1063 
replicate (n=3 separate cultures for each timepoint). Cells were synchronized to G2 as in (Figure 1064 
3a). 1065 
(c) Protein synthesis rates of G2 (blue) and mitotic (red) L1210 cells after 4 h treatment with 1066 
indicated mitotic inhibitors. The proportion of mitotic cells relative to control is indicated below 1067 
(mean±SD). (n=4 separate cultures). P-values obtained using ANOVA followed by Tukey’s 1068 
posthoc test. 1069 
(d) Mass-normalized MAR of 10 nM Vinblastine or 10 nM Vincristine treated L1210 cells in late 1070 
G2 and mitosis. Dashed vertical line indicates the approximate mitotic entry. Solid dark lines 1071 
indicate the mean and light areas represent ±SD. n refers to number of individual cells analyzed. 1072 
Drug treatments started 1-4h prior to mitotic entry and were maintained through the experiment. 1073 
 1074 
 1075 
Figure 5: Cells in metaphase and anaphase display stage specific mass accumulation 1076 
regulation independently of cell elongation 1077 
(a) Representative L1210 cell phase contrast (grey) and mAG-hGeminin cell cycle reporter (green) 1078 
images in control (n=9 cells) and 200 nM Tozasertib (n=6 cells) treated cells. The degradation of 1079 
mAG-hGeminin indicates metaphase-to-anaphase transition. No cytokinesis takes place under 1080 
Tozasertib treatment. 1081 
(b) Mass-normalized MAR of control (blue) and 200 nM Tozasertib (orange) treated L1210 cells. 1082 
Note that Tozasertib prolonged early mitosis, but most cells still displayed increased MAR after 1083 
G2/M transition (see Figure 5-figure supplement 2a). Dashed vertical line indicates the metaphase-1084 
to-anaphase transition. Solid dark lines indicate the mean and light areas represent ±SD. n refers to 1085 
number of individual cells analyzed. Arrows reflect typical time of G2/M transition for each 1086 
sample. Drug treatment started 1-4h prior to mitotic entry and was maintained through the 1087 
experiment. 1088 
(c, d) Mass-normalized MAR of control (blue) and 5 µM STLC (red) treated L1210 cells (f). 1089 
Dashed vertical lines indicate the approximate mitotic entry (for both samples) and metaphase-to-1090 
anaphase transition (only applies to control). Solid dark lines indicate the mean and light areas 1091 
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represent ±SD. Arrows indicate time points from which data was extracted to generate the boxplot 1092 
in (g). n refers to number of individual cells analyzed. P-values were obtained using ANOVA 1093 
followed by Tukey’s posthoc test.  1094 
 1095 
In all boxplots, line: median, box: interquartile range, whiskers: 5-95%. See Materials and methods 1096 
for details on MAR analysis resolution for this figure.  1097 
 1098 
Figure 6: CDK1 drives mitotic growth through 4E-BP1 and cap-dependent protein synthesis 1099 
(a) Schematic of growth regulation pathways. Chemical and genetic inhibitors (red), kinases 1100 
(yellow) and the measured downstream consequences (green) are shown. 1NM-PP1 mediated 1101 
inhibition of CDK1 is dependent on kinase mutation. 1102 
(b) L1210 cell levels of phosphorylated 4E-BP1 (Thr37/46) in G2 (blue) and mitosis (red) after 2 h 1103 
treatment with 250 nM TORIN-1, 1 µM RO-3306 or 50 nM OTSSP167. (n=5-6 separate cultures). 1104 
(c) Protein synthesis rates of G2 (blue) and mitotic (red) L1210 cells after 2 h treatment with 1 µM 1105 
RO-3306 or 50 nM OTSSP167. (n=6 separate cultures). 1106 
(d) Mass-normalized MAR of control, 1 µM RO-3306 or 30 nM OTSSP167 treated L1210 cells. 1107 
Solid dark lines indicate the mean and light areas represent ±SEM. Arrows reflect typical time of 1108 
G2/M transition for each sample. n refers to number of individual cells analyzed. Drug treatments 1109 
started 1-4h prior to mitotic entry and were maintained through the experiment.  1110 
(e) DT40 CDK1as cell protein synthesis rates in G2 (blue) and mitosis (red) after 5 h treatment with 1111 
1NM-PP1. (n=5-8 separate cultures). 1112 
(f) Mass-normalized MAR of control or 200 nM 1NM-PP1 treated DT40 CDK1as cells. Solid dark 1113 
lines indicate the mean and light areas represent ±SEM. Arrows reflect typical time of G2/M 1114 
transition for each sample. n refers to number of individual cells analyzed. Drug treatments started 1115 
1-4h prior to mitotic entry and were maintained through the experiment.  1116 
(g) Protein synthesis rates of G2 (blue) and mitotic (red) L1210 cells expressing scrambled or 4E-1117 
BP1 targeting shRNAs. The cells were treated for 2 h with 1 µM RO-3306 before sample 1118 
preparation. (n=6 separate cultures). 1119 
(h) Protein synthesis rates of G2 (blue) and mitotic (red) L1210 cells after 2 h treatment with 1 µM 1120 
RO-3306, 5 h treatment with 50 µM 4EGI-1 or combined treatment with RO-3306 and 4EGI-1. 1121 
(n=6-8 separate cultures). 1122 
 1123 
All P-values were obtained using ANOVA followed by Tukey’s posthoc test. 1124 
 1125 
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Figure 7: CDK1-driven mitotic protein synthesis supports daughter cell growth  1126 
(a) MAR during indicated stages of cell cycle in control, 1 µM RO-3306, 30 nM OTSSP167 or 100 1127 
nM cycloheximide (CHX) treated L1210 cells. The MAR values were normalized to control mean 1128 
at each stage. n refers to number of individual cells analyzed. Drug treatments started 1-4h prior to 1129 
mitotic entry and were maintained through the experiment. 1130 
(b) MAR during indicated stages of cell cycle in control or 200 nM 1NM-PP1 treated DT40 1131 
CDK1as cells. The MAR values were normalized to control mean at each stage. n refers to number 1132 
of individual cells analyzed. Drug treatment started 1-4h prior to mitotic entry and was maintained 1133 
through the experiment. 1134 
(c & d) MAR of newborn L1210 G1 cells from control and from cells that have undergone mitosis 1135 
in the presence of 1 µM RO-3306 (c) or from cells that have been arrested to mitosis for 4 h with 1136 
STLC before releasing to undergo cytokinesis (d). Data acquired using serial SMR (see Figure 7–1137 
figure supplement 2 for details). n refers to number of individual cells analyzed. 1138 
(e) Protein synthesis rates of G1 L1210 cells expressing a scrambled or 4E-BP1 targeting shRNA 1139 
after the cells progressed through mitosis in the presence or absence of 1 µM RO-3306. Two 1140 
timepoints (3h and 8h) after G2 release are shown. (n=4 separate cultures). 1141 
(f) Long-term growth, as measured by cell confluency, in L1210 cells that have been arrested to 1142 
mitosis for 4 h with STLC or MG132 before releasing to undergo cytokinesis (n=5 separate 1143 
cultures, top), or have undergone mitosis in the presence of 1 µM RO-3306 (n=6 separate cultures, 1144 
bottom). Dark colors indicate mean and light areas indicate ±SEM. 1145 
 1146 
In (a) and (e), P-values obtained using ANOVA followed by Tukey’s posthoc test. In (b-d), P-1147 
values obtained using two-tailed Welch’s t-test. In boxplots, line: median, box: interquartile range, 1148 
whiskers: 5-95%. 1149 
 1150 
 1151 
  1152 
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Supplementary Figure Legends 1153 
 1154 
Figure 1 – Figure Supplement 1: Suspended microchannel resonator (SMR) setups and noise 1155 
characterization. 1156 
(a) Left, schematic of automated fluid control strategy for continuous single-cell mass 1157 
measurements. Steps in order: 1) A single cell (pink circle) flows left to right. Flow direction is 1158 
depicted in blue dashed lines. 2) Once cell reaches right side of the cantilever, flow is stopped (~ 50 1159 
s). 3) Flow direction is reversed, and the cell flows to the left side. 4) Flow is stopped again (~ 50 1160 
s). These steps (1-4) are repeated to continuously measure the buoyant mass of the cell as it grows 1161 
within the SMR. Right, schematic of SMR resonant frequency readout during steps depicted on left. 1162 
Cell buoyant mass (i.e., height of the two side peaks) increases between each measurement, which 1163 
corresponds to cell growth. 1164 
(b) SMR measurement noise quantification by repeated buoyant mass measurements of a single 12 1165 
µm polystyrene bead. (n=102 repeated measurements). 1166 
(c) Representative 40 min buoyant mass trace of a L1210 cell (n=180 individual cells). Pink dots 1167 
depict each measurement and gray error bars depict the 99% confidence interval (CI) obtained from 1168 
the repeated bead measurement shown in (b). 1169 
(d) Orientation-dependent noise in mass measurements. Representative buoyant mass trace of a 1170 
L1210 near mitosis is shown (n=180 individual cells). Before anaphase L1210 cells are highly 1171 
spherical and orientation dependent noise is minimal (left inset, red box). The SD is comparable to 1172 
the noise obtained from repeated bead measurement. After cell elongation (singlet to doublet), noise 1173 
increases due to orientation dependent error (right inset, green box). See Materials and methods for 1174 
additional details. 1175 
(e) Cell elongation induced buoyant mass measurement bias in cytokinesis. Representative buoyant 1176 
mass trace of a L1210 near mitosis is shown with (red) and without (grey) the cell elongation 1177 
correction in data analysis (n=180 individual cells). The yellow area represents the duration of cell 1178 
elongation, as in panel (d). See Materials and methods for additional details. 1179 
 1180 
Figure 1 – Figure Supplement 2: Detection of cell cycle transitions. 1181 
(a) A table summarizing cellular changes and corresponding signals measured in SMR. (*1 refers to 1182 
(Son et al., 2015a); *2 refers to (Kang et al., 2019)). Node deviation is an acoustics-based 1183 
measurement that depends on cell shape and stiffness (Kang et al., 2019). 1184 
(b) Example buoyant mass (black) and node deviation (raw: light red, filtered: red) traces of a 1185 
L1210 during G2 and M-phase (n=180 individual cells). ∆Node deviation represents a change in 1186 
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node deviation compared to median of first 15 data points. Node deviation decreases as a cell enters 1187 
mitosis (arrowhead #1) due to cell swelling (Kang et al., 2019), which starts immediately after 1188 
mitotic entry (Son et al., 2015a; Zlotek-Zlotkiewicz et al., 2015). This is followed by another rapid 1189 
decrease in node deviation after metaphase-to-anaphase transition (arrowheads #3 and #4). Vertical 1190 
lines mark G2/M and metaphase-to-anaphase (M/A) transition, respectively. A cell morphology 1191 
acquired by on-chip imaging at indicated time points (arrow heads and numbers) are shown on top. 1192 
Scale bars denote 10 µm. 1193 
(c) Example buoyant mass (black), node deviation (raw: light red, filtered: dark red) and FUCCI 1194 
(green, mAG-hGem) traces of a L1210 FUCCI cell during G2 and M-phase (n=12 individual cells). 1195 
Fluorescence detection limit of our system is shown by a green band in the bottom. An abrupt loss 1196 
of FUCCI signal (degradation of mAG-hGem) marks the metaphase-to-anaphase transition. 1197 
 1198 
Figure 2 – Figure Supplement 1: Mass accumulation rate (MAR) analysis. 1199 
(a) Schematic of obtaining the average MAR/mass for late G2, early mitosis and cytokinesis. The 1200 
following steps have been performed in order. First, metaphase-to-anaphase transition (green star) 1201 
and approximate mitotic entry were specified based on biophysical and fluorescence markers (see 1202 
Figure 1-figure supplement 2). Second, late G2, early mitosis and cytokinesis were selected as 1203 
described in the Materials and methods. Briefly, for L1210 cells shown here, cytokinesis was set as 1204 
a 50 min period after metaphase-to-anaphase transition; early mitosis was set as a 30 min period 1205 
before metaphase-to-anaphase transition, and late G2 was set as 30 min period prior to the start of 1206 
early mitosis. Vertical dashed lines separate each stage. Third, buoyant mass traces (grey) during 1207 
each stage were linearly fitted and the slope of each line represents the MAR. Finally, MAR of each 1208 
stage was divided by the average mass within that stage. Cell elongation period (12 min for L1210 1209 
cells) is depicted in yellow. Orange circle denotes daughter cell abscission.  1210 
(b) Schematic of obtaining MAR with high-temporal resolution. The following steps has been 1211 
performed in order. First, metaphase-to-anaphase transition (green star) was specified as described 1212 
above. Second, a 10 min period around metaphase-to-anaphase is selected (i.e., ±5 min around 1213 
metaphase-to-anaphase). Third, the rest of the buoyant mass trace is divided in to additional 10 min 1214 
periods, each shifted by 5 min. Fourth, each section is then fitted with a linear line, and the slope of 1215 
each fitted line represents MAR at the center of that line. For example, 0.68, which represents the 1216 
slope of 10 min period around metaphase-to-anaphase transition, represents MAR at t = 0 (see inset 1217 
on right). Lastly, the MAR at each period is divided by the average mass of that 10 min period to 1218 
obtain MAR/mass. Note that for Figure 5, similar analysis was carried out using 4 min periods, each 1219 
shifted by 2 min.  1220 
42 
 
(c) MAR vs time trace that was obtained from data in panel (b) after smoothing of the buoyant mass 1221 
trace.  1222 
(d) MAR/mass vs time trace obtained from panel (b) after smoothing of the buoyant mass trace. 1223 
MAR/mass trace of elongation corrected (magenta) and uncorrected (purple) are plotted together for 1224 
comparison.  1225 
 1226 
Figure 2 – Figure Supplement 2: MAR in different growth conditions and cell types. 1227 
(a) Mass-normalized MAR of L1210 cells in late G2 and M-phase when grown under indicated 1228 
FBS and glucose conditions. For comparison, in Fig. 2a (as well as all other figures), L1210 cells 1229 
were grown in 10% FBS and 11 mM glucose conditions. M/A denotes the metaphase-to-anaphase 1230 
transition, G2/M denotes the approximate mitotic entry, both of which are indicated with dashed 1231 
vertical lines. Solid dark blue lines indicate the mean and light blue areas represent ±SD. n refers to 1232 
number of individual cells analyzed. 1233 
(b) Mass-normalized MAR of indicated cell types in late G2 and M-phase. Note that L1210 cells 1234 
obtained from ECACC did not display an increase in MAR in early mitosis. All other L1210 1235 
experiments were done with cells obtained from ATCC. M/A denotes the metaphase-to-anaphase 1236 
transition, G2/M denotes the approximate mitotic entry, both of which are indicated with dashed 1237 
vertical lines. Solid dark blue lines indicate the mean and light blue areas represent ±SD. n refers to 1238 
number of individual cells analyzed. 1239 
(c) Reproducibility of L1210 cell mitotic growth dynamics between different SMR devices and over 1240 
multiple years. Note that multiple batches of L1210 cells were analyzed over the duration of this 1241 
study and similar mass accumulation behavior was always observed. n refers to number of 1242 
individual cells analyzed.  1243 
 1244 
Figure 3 – Figure Supplement 1: Single-cell protein synthesis assays in mitotic cells. 1245 
(a) Top left, schematic indicating the approximate cell cycle stages separated by Cyclin B1 and 1246 
phospho-Histone H3 (Ser10) antibody labeling. Bottom, representative FACS scatter plots 1247 
indicating the separation of early (prophase to metaphase) and late (anaphase to telophase) mitotic 1248 
L1210 cells. Arresting cells to metaphase using STLC increases the number of cells in early mitosis 1249 
but decreases the number of cells in late mitosis, validating the cell cycle separation. Top right, a 1250 
histogram indicating O-propargyl-puromycin (OPP) protein synthesis assay specificity, by 1251 
comparing control (orange) and 100 µM cycloheximide (CHX) (blue) treated samples. (n=6 1252 
separate cultures for control, 3 separate cultures for Blank, CHX and STLC samples) 1253 
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(b) Representative image of control L1210 cells labeled with OPP and phospho-Histone H3 (Ser10) 1254 
antibody (n=12 fields of view). An early mitotic cell (white arrow), with phospho-Histone H3 1255 
(Ser10) labelling but not fully compacted chromatin, displays OPP incorporation comparable to 1256 
OPP incorporation in non-mitotic cells (cells without arrows). A metaphase cell (pink arrowhead), 1257 
with phospho-Histone H3 (Ser10) labelling and compacted chromatin, displays low OPP 1258 
incorporation. Dashed yellow lines indicate cell outlines. 1259 
(c) Protein synthesis rates of G2, early mitotic and late mitotic L1210 cells. Early and late mitotic 1260 
cells were separated as shown in (a). Chemical treatment with 5 µM STLC lasted 2 h and with 100 1261 
µM CHX lasted 30 min. Data in late mitosis after STLC treatment is indicated with light green bar, 1262 
as this population had too few cells for a reliable analysis. (n=3-6 separate cultures).  1263 
(d) Protein synthesis rates of G2 and mitotic L1210 cells after 4 h treatment with 100 nM CHX. 1264 
(n=4 separate cultures). 1265 
 1266 
In (c) and (d), data depicts mean±SD. P-values obtained using ANOVA followed by Tukey’s 1267 
posthoc test. 1268 
 1269 
Figure 5 – Figure Supplement 1: Mitotic cell swelling affects MAR, but not protein synthesis 1270 
in early mitosis. 1271 
(a) Mass-normalized MAR of control (blue) and 10 µM EIPA (pink) treated L1210 cells. Dashed 1272 
vertical lines indicate the approximate mitotic entry and metaphase-to-anaphase transition. Solid 1273 
dark lines indicate the mean and light areas represent ±SD. n refers to number of individual cells 1274 
analyzed. Drug treatment started 1-4h prior to mitotic entry and was maintained through the 1275 
experiment. 1276 
(b) Quantification of L1210 cell maximal growth rate observed in late G2 and in mitosis when 1277 
treated with 10 µM EIPA (n=12 cells, each an independent experiment). P-values obtained using 1278 
two-tailed Welch’s t-test. 1279 
(c) Quantifications of data displayed in panel a. Mass-normalized MAR of control (blue) and EIPA 1280 
(pink) treated L1210 cells were analyzed as a function of time after mitotic entry. n refers to number 1281 
of individual cells analyzed. P-values were obtained using ANOVA followed by Tukey’s posthoc 1282 
test. 1283 
(d) Ratio of protein synthesis rate between mitotic and G2 L1210 cells after release from G2 arrest 1284 
in to control (blue) or 10 µM EIPA (pink). Light green area displays the typical protein synthesis 1285 
ratio between mitotic and G2 cells in the absence of cell cycle synchronization. Each data point 1286 
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represents an individual replicate (n=3 separate cultures for each timepoint). Cells were 1287 
synchronized to G2 as in (Figure 3a).  1288 
 1289 
In all boxplots, line: median, box: interquartile range, whiskers: 5-95%. See Materials and methods 1290 
for details on MAR analysis resolution for this figure.  1291 
 1292 
Figure 5 – Figure Supplement 2: The low MAR in metaphase and anaphase are not explained 1293 
by cell elongation or time spent in mitosis. 1294 
(a) Examples of individual 200 nM Tozasertib treated L1210 mass-normalized MAR traces. Note 1295 
that although MAR remains positive around metaphase-to-anaphase transition, the absence of 1296 
cytokinesis in these cells does not remove the overall dynamics of MAR (See Figure 2d for control 1297 
dynamics). Dashed vertical lines indicate the approximate mitotic entry and metaphase-to-anaphase 1298 
transition. Drug treatment started 1-4h prior to mitotic entry and was maintained through the 1299 
experiment. 1300 
 (b) Mass-normalized MAR of 25 µM Blebbistatin treated L1210 cells. Solid dark blue line 1301 
indicates the mean and light areas represent ±SD (n=9 individual cells, each from separate 1302 
experiment). Dashed vertical lines indicate the approximate mitotic entry and metaphase-to-1303 
anaphase transition. Drug treatment started 1-4h prior to mitotic entry and was maintained through 1304 
the experiment. 1305 
(c) MAR/mass of control (blue) and Nocodazole (dark red) treated L1210 cells were analyzed as a 1306 
function of time after mitotic entry. n refers to number of individual cells analyzed. P-values 1307 
obtained using two-tailed Welch’s t-test. In boxplots, line: median, box: interquartile range, 1308 
whiskers: 5-95%. 1309 
 1310 
See Materials and methods for details on MAR analysis resolution for this figure.  1311 
 1312 
Figure 6 – Figure Supplement 1: 4E-BP1 is phosphorylated in mitosis 1313 
(a) L1210 cell levels of phosphorylated 4E-BP1 (Thr37/46) in mitosis and G2. Antibody isotype 1314 
control is shown as a specificity control. (n=5-6 separate cultures). P-values obtained using 1315 
ANOVA followed by Tukey’s posthoc test. 1316 
(b) Representative image of L1210 cells in interphase (light blue arrow heads) and in early mitosis 1317 
(yellow arrows) with DNA, α-Tubulin and p-4E-BP1 (Thr37/46) labeling (n=15 fields of view). 1318 
Mitotic cells were identified based on DNA condensation and α-Tubulin morphology. DNA and p-1319 
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4E-BP1 (Thr37/46) labeling within the orange box are shown separately on the right. Scale bars 1320 
denote 10 µm. 1321 
(c) L1210 cell levels of phosphorylated 4E-BP1 (Thr37/46) in mitotic cells treated with or without 1322 
Lambda protein phosphatase. (n=3 separate cultures). P-values obtained using two-tailed Welch’s t-1323 
test. See Materials and methods for experimental details.  1324 
 1325 
Figure 6 – Figure Supplement 2: mTOR is active in mitosis but is not required for mitotic 1326 
protein synthesis. 1327 
(a) L1210 cell levels of phosphorylated S6RP (Ser235/236) in mitosis and G2. Antibody isotype 1328 
control is shown as a specificity control. (n=5-6 separate cultures).  1329 
(b) L1210 cell levels of phosphorylated S6RP (Ser235/236) in G2 (blue) and mitosis (red) after 2 h 1330 
treatment with 250 nM TORIN-1, 1 µM RO-3306 or 50 nM OTSSP167. (n=5-6 separate cultures). 1331 
(c) Protein synthesis rates of G2 (blue) and mitotic (red) L1210 cells after 2 h treatment with 250 1332 
nM TORIN-1. (n=4 separate cultures). 1333 
 1334 
All P-values obtained using ANOVA followed by Tukey’s posthoc test. 1335 
 1336 
Figure 6 – Figure Supplement 3: Kinase inhibitors which have MELK kinase as an off-target 1337 
do not reduce mitotic protein synthesis. 1338 
(a) Protein synthesis rates of G2 (blue) and mitotic (red) L1210 cells after 3 h treatment with 1 µM 1339 
SNS-032 (CDK2 inhibitor) or 50 nM Tozasertib (Aurora kinase inhibitor), or 5 h treatment with 1 1340 
µM GSK 626616 (DYRK kinase inhibitor). (n=5-8 separate cultures). P-values obtained using two-1341 
tailed Welch’s t-test. 1342 
(b) Ratio of protein synthesis rates between mitotic and G2 L1210 cells after 3 h treatment with 1343 
OTSSP167, Defactinib (also known as PF-04554878), PF-3758309 (also known as PF-309) or 1344 
Nintedanib (also known as BIBF 1120), all of which inhibit MELK kinase with sub-micromolar 1345 
affinity (Klaeger et al., 2017). Light blue area indicates the typical range observed in control cells. 1346 
(n=4 separate cultures). Note that OTSSP167 is a nonspecific multikinase inhibitor (Klaeger et al., 1347 
2017), making it likely that MELK kinase does not contribute to the drug induced mitotic growth 1348 
reduction. 1349 
(c) Representative FACS scatter plots indicating the cell cycle distribution after 6 h treatment with 1350 
indicated chemicals. The relative portion of cells in G1/S, G2 and mitosis are indicated (mean±SD). 1351 
(n=4-6 separate cultures). Note that OTSSP167 reduced mitotic entry, a phenotype typical for 1352 
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CDK1 inhibition, while the alternative MELK inhibitors did not display similar cell cycle profile. 1353 
CDK1 is one of the off-targets of OTSSP167 (Klaeger et al., 2017). 1354 
 1355 
Figure 6 – Figure Supplement 4: shRNA mediated knockdown of 4E-BP1 in L1210 cells. 1356 
(a) Histogram of 4E-BP1 protein levels analyzed by immunostaining and flow cytometry in L1210 1357 
cells stably expressing the indicated shRNAs.  1358 
(b) Quantifications of data in panel (a). n=3 separate cultures. Note that the difference in 4E-BP1 1359 
knockdown efficiency between the two 4E-BP1 targeting shRNAs is likely to explain the 1360 
differences observed between these two cell lines in Figure 6e.  1361 
(c) Proliferation rate of control and 4E-BP1 knockdown cells. Note that the lack of strong 1362 
proliferation phenotypes likely reflects the optimal growth conditions where 4E-BP1 is maintained 1363 
phosphorylated & inactivated.  1364 
 1365 
Figure 7 – Figure Supplement 1: Correlations between mitotic and G1 cell MAR 1366 
Correlation plot between mother cell MAR in early mitosis (30 min section prior to M/A transition) 1367 
and daughter cell MAR in early G1 (first 30 min after abscission) for control, 1 µM RO-3306 and 1368 
50 nM OTSSP167 treatments. R-squared values are depicted on right.  1369 
 1370 
Figure 7 – Figure Supplement 2: Daughter cell growth rate measurement workflow 1371 
(a) Workflow for measuring MAR, protein synthesis and proliferation rate of G1 cells that have 1372 
passed through mitosis under control or drug perturbed conditions. Mitotic RO-3306 treatments 1373 
were washed away 3h after G2 release.  1374 
(b) Top, schematic of serial SMR. Cells (pink circles) flow through 12 mass sensing cantilevers 1375 
separated by delay channels to obtain consecutive mass measurements before being discarded. 1376 
Bottom, the consecutive mass measurements (colored data points) are used to assign a growth (mass 1377 
accumulation) rate (dashed red line) for each cell. The serial SMR does not allow long-term 1378 
monitoring of growth but enables much higher MAR measurement throughput than the single 1379 
cantilever SMR shown in (Figure 1 – figure supplement 1a). 1380 
(c) Representative serial SMR data from control L1210 cells (n=4 independent experiments). G2 1381 
synchronized cells were released and the single-cell MAR was monitored by continuously sampling 1382 
the population. Buoyant mass measured at each cantilever is displayed with different color, as 1383 
shown at the bottom of (a). The G1 cell growth rates can be quantified by analyzing MAR only 1384 
from the small (25 to 60 pg) cells. 1385 
 1386 
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Figure 7 – Figure Supplement 3: Daughter cells protein synthesis rates in G1 following mitotic 1387 
growth inhibitions 1388 
Protein synthesis rates of G1 L1210 cells from control (normal mitosis) and from cells that have 1389 
undergone mitosis in the presence of 1 µM RO-3306 or from cells that have been arrested to mitosis 1390 
for 4 h with STLC before releasing to undergo cytokinesis. (n=3 separate cultures). 1391 
aFigure 1. Miettinen, Kang, et al. 2018.
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